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Congenital heart defects are the most prevalent birth defect, and maternal cigarette 
smoking is a known risk factor. Nicotine replacement therapies are recommended to pregnant 
women who smoke to aid in smoking cessation, as this alternative is thought to be much safer 
compared to cigarette smoking. However, these products contain nicotine, and the safety of 
nicotine on the developing heart is not well known. In this thesis, a mouse model was used to 
test the hypothesis that maternal nicotine exposure (MNE) during pregnancy leads to 
congenital heart defects and coronary artery defects in the offspring of mice. MNE resulted in 
both congenital heart defects and hypoplastic coronary arteries at a significant incidence of 
43% and 31%, respectively. Moreover, MNE resulted in altered gene expression of key 
cardiogenic regulators and higher levels of oxidative stress in the embryonic hearts. 
Myocardial cell proliferation and epithelial-to-mesenchymal transition was lower with MNE. 
In summary, MNE resulted in a higher incidence of congenital heart defects and coronary 
artery defects. To our knowledge, this study demonstrated, for the first time, that maternal 
nicotine exposure in a mouse model induces a range of congenital heart defects, and impairs 
coronary artery vasculature. These findings could provide insight into the dangers of nicotine 
replacement therapy for the offspring during pregnancy. 
Keywords 
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Chapter 1  
1 Introduction 
The embryonic development of the heart involves complex stepwise 
morphogenetic events, including cardiomyocyte differentiation and proliferation, 
specification of cardiac lineages, formation and patterning of the primitive heart tube, 
looping morphogenesis, and finally, chamber maturation. A unique interplay of 
cardiogenic transcription factors and growth factors that are secreted from both 
cardiomyocytes and non-cardiomyocyte lineages govern the occurrence of these events. 
Mutation in cardiogenic genes that encode for these transcription factors and growth factors 
are associated with congenital heart defects (CHDs). 
Maternal cigarette smoking is a known risk factors for the development of CHDs. 
During pregnancy, there are different strategies available to help quit smoking, such as 
counseling and behavioural therapy. However, when failed to be effective, pharmacology, 
such as nicotine replacement therapies (NRTs) are also recommended as a safer alternative 
to cigarette smoking to aid in smoking cessation. The focus of this thesis is on the effect of 
maternal nicotine exposure on fetal heart development. Before delving into the 
pathophysiology of maternal nicotine exposure it is important to first discuss normal heart 
development and congenital heart defects.  
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1.1 Embryonic Heart Development 
The first organ to form and function in early embryonic life of all vertebrates is the 
heart, which is critical to ensure proper nutrient and oxygen supply to the developing 
embryo 1. Cardiogenesis begins in the third week of gestation in humans and on embryonic 
day (E)7 in the mouse 2. Cardiogenesis requires the integration of three pools of progenitor 
cells: the first heart field (FHF), second heart field (SHF), and cardiac neural crest (CNC) 
cells 3. Throughout development, cardiac progenitors undergo extensive proliferation, 
remodeling, migration and differentiation, which several transcription factors, epigenetic 
regulators, and signaling molecules facilitate to form the various structures of the heart 3. 
Heart development is a complex process that includes the formation of the linear heart tube, 
cardiac looping and chamber alignment, septation, as well as development of the coronary 
vasculature (Figure 1). Understanding the molecular mechanism of heart development is 
absolutely necessary to be able to identify the etiology of different cardiac defects that can 






Figure 1. Heart development in the mouse.  
Top and bottom panels show oblique and frontal views, respectively, of cardiac progenitor 
cells in the mouse embryo. By E7.5 FHF progenitors form a cardiac crescent and by E8.0 
will have merged to form the primary heart tube. SHF progenitors migrate into the heart 
tube and elongate the arterial and venous poles. The heart tube will undergo a rightward 
looping, CNC cells also migrate into the outflow tract (OFT) to further cardiac 
development. V, ventricle; A, atrium; CT, conotruncus; RA, right atrium; LA, left atrium; 
AS, aortic sac; RV, right ventricle; LV, left ventricle; AVV, atrioventricular valves; Ao, 
aorta; PA, pulmonary artery; DA, ductus arteriosus; RSCA, right subclavian artery; RCA, 
right carotid artery; LCA, left carotid artery; LSCA, left subclavian artery; FHF first heart 
field; SHF, second heart field; CNC, cardiac neural crest. Figure adapted with 





1.1.1 Formation of the Primitive Heart Tube 
Most structures of the heart are formed through cardiac progenitor cells from the 
FHF and SHF, both of which arise from the mesoderm germ layer during gastrulation 4-6. 
On E7.5 in the mouse and week 3 of gestation in humans, cells of the anterior lateral plate 
mesoderm migrate to form a crescent-shaped structure at the cardiogenic plate, which is 
the anterior region of the embryo that will subsequently give rise to the heart 2, 7, 8. The 
cardiac specific transcription factor, Nkx2.5 begins to be expressed from the cells at this 
time, in order to regulate the expression of genes that regulate the differentiation of 
cardiomyocytes 9. Another early cardiogenic transcription factor, Gata4, also begins to be 
expressed, interacting with Nkx2.5 to regulate gene expression at this stage in development 
10. The 2 edges of the crescent-shaped structure proliferate and migrate toward the midline 
to join and form the primitive heart tube by E8 in mice. Peristaltic contractions are initiated 
at this stage 11, 12. It has been demonstrated that Gata4 is necessary for fusion of the cardiac 
crescent 11. Progenitor cells from the FHF develop into the left ventricle and have partial 
involvement in the development of the atria 2, 3. The SHF is derived from the pharyngeal 
mesoderm which lies dorsal and medial to the primary crescent 13-15 The SHF progenitor 
cells elongate the linear heart tube by migrating to both of its poles 16. The SHF contributes 
to the formation of the right ventricle, as well as portions of the outflow tract, semilunar 
valves, and atria; along with playing an important role in remodeling and septation of the 
heart 3, 8, 17, 18. After elongation of the linear heart tube, it resembles an inverted “Y”. 
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1.1.2 Cardiac Looping 
A rightward looping of the heart occurs during E8.25 to E10.5 in mice and day 22 
to 32 in human embryos 19, creating the position of the future chambers of the heart (Figure 
1). Proper looping of the heart is regulated by asymmetrical expression of the Nodal gene 
and is necessary for correct orientation of the atria and ventricles. The Nodal gene is self-
activated in the left lateral plate mesoderm and signals the rightward direction of looping. 
Nodal induces expression of homeobox gene Pitx2 which is localized to the left lateral 
plate mesoderm and heart field. The atrial end then moves dorso-cranially, leading to 
formation of the right and left atrium 20. The ventricles are positioned posteriorly and 
connected to the common outflow tract 21. If expression or patterning of Nodal or Pitx2 is 
impaired, this can result in a leftward looping or lack of looping 22, 23. This cardiac looping 
is important to ensure that the chambers are correctly positioned and able to connect to the 
common outflow tract. After looping of the heart, the septal walls along the atria, ventricles 
and outflow tract begin to develop and separate the heart into 4 chambers with distinct 
inflow and outflow vessels. 
1.1.3 Septation of the Heart 
1.1.3.1 Septation of Atria and Ventricles 
For complete partitioning of the primitive heart several septation events must take 
place. Following cardiac looping the heart tube is divided into atrial, ventricular, and 
outflow tract (OFT) components. Septation of atria and ventricles occurs throughout E10 
to E14.5 in mice and during weeks 5 to 7 in humans 19, 24. Formation of the endocardial 
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(EC) cushion at the common atrioventricular (AV) junction of the looped heart is required 
for septation of the atria and ventricles and formation of the AV valves 20, 25. The EC 
cushion is composed of an accumulation of extracellular matrix, termed cardiac jelly. 
After the looping of the heart, the myocardium initiates deposition of extracellular 
matrix in parts of the AV canal and outflow tract. As this extracellular matrix or cardiac 
jelly builds between the myocardial and endocardial cell layers it forms a protruding 
acellular structure. Endocardial cells from the cardiac cushion migrate toward the cardiac 
jelly as they undergo endothelial-to-mesenchymal transition (EndMT), which form the 
endocardial cushion 26. The part of the endocardial cushion that is termed the AV cushion 
is the portion between the dorsal and ventral sides of the AV canal. The AV cushion 
participates in the septation of the atria and ventricles, as well as AV valve formation 26. 
Thus, endocardial cushion development is crucial for proper heart development and 
function.  
Septation of the atrium occurs after the development of 2 septal structures, the 
septum primum and septum secundum 19, 26. The septum primum grows downward from 
the roof of the atrium at E9.5, which begins to divide the single atrium into right and left 
chambers. This septum continues to grow downward until it reaches the EC cushion at the 
AV canal. Gata4 and Tbx5 play a role in regulating atrial septation 27, 28. Gata4 also plays 
a role in driving progenitor proliferation by activating cell cycle genes Cyclin D2 and 
Cyclin-dependent kinase 4 (Cdk4) 27. eNOS also plays a role in septation, as septal defects 
were observed in 75% of eNOS knockout mice 29. The septum primum does not fully fuse 
with the AV cushion, and the space between is referred to as the ostium primum. This 
opening allows for the shunting of blood between the right and the left atria and will 
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eventually close as it fuses with the AV cushion by E12.5. Before closure of the ostium 
primum, a secondary foramen appears by apoptosis in the anterior side of the septum 
primum 19. This opening, termed the foramen secundum, enables a continuous shunting of 
blood between the atria when the ostium primum is closed. The muscular septum secundum 
begins to grow downward, just to the right of the septum primum at E13.5. As the septum 
secundum grows downward, it covers the foramen secundum, but only partially covers the 
posterior inferior surface of the septum primum. This leaves an opening which is called the 
foramen ovale 30. The physiological importance of the foramen ovale will be discussed in 
the below section, fetal heart physiology. 
Septation of the ventricles occurs at the same time between E10 to E14.5 24, 26. The 
ventricular septum has 2 parts, the muscular septum and the membranous septum. As the 
ventricles of the primary heart tube grow, a muscular septum forms in the middle. The 
muscular septum grows from the apical wall of the ventricles towards the AV cushion. The 
muscular septum does not fuse with the AV canal at this stage, leaving an opening between 
the left and right ventricles. The membranous septum will grow downward from the AV 
cushion to meet the muscular septum to separate the ventricles into left and right chambers 
31. 
1.1.3.2 Septation of Outflow Tract 
The right and the left ventricles share a common outflow tract in early development, 
called truncus arteriosus. At E10, septation of the truncus arteriosus begins, and by E14.5, 
it is fully divided into the aorta and pulmonary artery 32. In the midline of the truncus 
arteriosus a spiral septum forms. This septum grows downward and fuses with the 
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interventricular septum19, 32. This outflow tract septum creates two great arteries, the aorta 
and pulmonary artery, giving them dorsal-ventral orientation 32. Loss of this orientation 
pattern will result in improper connection of the aorta and pulmonary artery to the left and 
right ventricular chamber, respectively. 
1.1.4 Aortic and Pulmonary Valve Development 
Cardiac valve development begins on day E9.5 in the mouse, and days 31 to 35 of 
gestation in humans, with formation of the endocardial (EC) cushions in the AV Canal and 
outflow tract 31, 33. EC cushion formation begins with endothelial to mesenchymal 
transformation (EndMT), initiated by signals from the endocardial cells and myocardium, 
to promote transformation 34. The resultant mesenchyme cells are part of the progenitor 
cells that give rise to developed valve structures. Members of the TGF-𝛽 family are 
required for EndMT, and EC cushion formation is initiated by Bmp2 and Bmp4 expression 
in the AV canal and OFT myocardium. These genes are important in activating Tbx2 
expression to suppress the expression of chamber-specific genes and promote extracellular 
matrix deposition to form the cardiac jelly 35, 36. Bmp2 has also been demonstrated to 
increase TGF-𝛽2. TGF-𝛽2 is involved in the initiation of EndMT of endothelial cells to 
invade and populate the cardiac jelly in order to form the EC cushion 37, 38. Downstream of 
TGF-𝛽2 and Bmp2 signaling is the activation of Snail1 and Slug expression. Snail1 and 
Slug are pro-EndMT factors that result in decreased VE-cadherin expression, and allow for 
the delamination process 36. TGF-𝛽2 also plays an important role in valve remodeling, as 
knockout mice have demonstrated thickened aortic and pulmonary valves 39. Another 
critical pathway for valve development is through Notch1, which is highly involved in 
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EndMT by promoting the expression of both TGF-𝛽2 and Snail1 40. Individual valve 
leaflets are apparent in mice around E13.5 and weeks 5 and 6 in humans.  The valves 
continue to develop by thinning, reshaping as well as remodeling of the extracellular matrix 
34. Notch1 plays an important role in valve remodeling, as loss of endothelial Notch1 results 
in thickened aortic and pulmonary valves 41. Notch1 also promotes nitric oxide production 
via a PI3-kinase/Akt pathway to phosphorylate eNOS, which is important for multiple 
stages of heart development 42. Expression of eNOS begins at E9.5 and is downregulated 
at E14.5. Following the proliferative stage, apoptosis-mediated remodeling is required for 
full maturation of the aortic and pulmonary valves. 
1.1.5 Physiology of the Fetal Heart 
The fetal circulation differs from postpartum circulation, as the fetus is dependent 
on the mother’s circulation for oxygen 43. In the adult, deoxygenated venous blood returns 
to the heart via the inferior and superior vena cava, and flows into the right atrium of the 
heart. This blood subsequently pumped into the right ventricle, and then is pumped into the 
pulmonary circulation via the pulmonary artery. Oxygenated blood returns to the heart 
from the lungs, via the pulmonary vein, into the left atrium. This blood is then pumped into 
the left ventricle, and subsequently pumped through the aorta to the systemic arteries to be 
distributed throughout the body 43. In the fetus, the lungs are not functionally active, and 
the placenta transfers nutrients and oxygen between the maternal and fetal circulation. The 
fetal heart structurally adapts, creating shunts, to pass blood in different directions. The 
foramen ovale, located between the right and left atrium, is an important shunt in the fetal 
heart that is very important to fetal circulation. Due to increased pressure in the right atria, 
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this shunt allows for the transfer of oxygenated blood from the right atrium to the left 
atrium. This oxygenated blood is pumped into the left ventricle and into the aorta, 
supplying the systemic circulation with oxygen. The ductus arteriosus is another shunt 
which shunts blood through a connection of the pulmonary artery to the aorta. Maternal 
circulation transfers oxygenated blood through the placenta to the fetus via the umbilical 
vein. Blood travels from the umbilical vein to the inferior vena cava and into the right 
atrium of the heart. Some of this blood is then pumped into the right ventricle, which is 
pumped into the pulmonary artery. As blood is pumped through the pulmonary artery, the 
high-pressure resistance of the pulmonary artery enables most of the blood to be shunted 
into the aorta via the ductus arteriosus. High oxygen tension and secretion of prostaglandin 
from the placenta keep the ductus arteriosus shunt open during fetal development 44. After 
birth, the newborn’s lungs inflate, causing a significant decrease in resistance in the 
pulmonary veins, allowing pulmonary flow to increase. Oxygen in the right atrium will 
decrease, and pressure will increase in the left atrium. This reverse pressure gradient causes 
the septum secundum to cover the foramen ovale, blocking the shunt to the left atrium. Due 
to the pressure differences, this flap closure is sufficient to eliminate reverse flow; complete 
closure and seal of the opening does not occur until years after birth. Shortly after birth, 
within hours to days, prostaglandin levels are lowered, resulting in closure of the ductus 
arteriosus 44. At this time, blocking of the shunts have occurred and there is no longer 




1.1.6 Development of the Coronary Vasculature 
The coronary vasculature originates from the ascending aorta at the aortic sinuses. 
The left coronary artery arises from the left posterior aortic sinus, and the right coronary 
artery from the anterior aortic sinus respectively 45. The coronary vasculature continues to 
branch toward the apex of the heart, supplying the cardiac muscle with oxygenated blood. 
Deoxygenated blood is collected into veins, which drain directly into the right atrium via 
the coronary sinus. There are three cell types that compose the coronary arteries: vascular 
smooth muscle cells, fibroblasts and endothelial cells. 
The coronary vasculature forms during 2 processes, both vasculogenesis and 
angiogenesis 46. Vasculogenesis is the de novo formation of the blood vessels by the 
production of new endothelial cells, and angiogenesis refers to the growth and remodeling 
of the primitive network into a complex network. During coronary artery development, 
vasculogenesis is initiated after formation of an epicardial layer at E10.5, followed by 
angiogenesis, where the vascular network further develops. The morphological aspects of 
vasculogenesis and the essential molecular factors in coronary artery development 
regulation in the embryonic heart will now be described.  
The progenitor cells that give rise to the coronary vasculature do not originate from 
the same primordial cells as the rest of the heart but originate from the proepicardial organ 
(PEO). The PEO is a transient developmental structure formed from a group of cells that 
emerge from a region close to the sinus venosus and the liver primordium 47-49. At E9.5 in 
mice, cells from the PEO migrate to the heart and proliferate to expand over the developing 
heart tube to form a layer called the epicardium 47-49. By E12.5 the epicardial layer fully 
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covers the heart. Some epithelial cells from the epicardium are destined to undergo 
epithelial-to-mesenchymal transition (EMT) and dissociate from the epicardial layer to 
migrate into the myocardium 50. Cells that undergo EMT are called epicardial derived cells 
(EPDCs). EPDCs proliferate and migrate into the myocardium where they differentiate 
into coronary vascular smooth muscle cells and cardiac fibroblasts, both of which 






Figure 2. Coronary artery development. 
At E9.5 cells from the proepicardial organ (PEO) migrate and translocate toward the 
myocardium to form a third layer over the surface of the looping heart termed the 
epicardium. Cells from the epicardium undergo epithelial-to-mesenchymal transition 
(EMT) and migrate through the subepicardium. The epicardium derived cells (EPDCs) 
differentiate into vascular smooth muscle cells and endothelial cells and cardiac fibroblasts, 
contributing to the coronary vasculature of the mature heart. Hif1a upregulates 
transcription factor Snail1, which downregulates cell adhesion protein E-Cadherin, 
allowing delamination and migration of EPDCs. Growth factors such as FGF promote 
EPDC migration, differentiation, and proliferation. TGF-ß: transforming growth factor-ß, 
TGFR: transforming growth factor receptor, DLL4: delta-like ligand 4, Hif1a: hypoxia-
inducible factor 1 alpha, FGF: fibroblast growth factor, FGFR: fibroblast growth factor 





 The transcription factor, hypoxia inducible factor 1 (Hif1), is responsible for initiating 
the transcriptional activation of genes involved in vasculogenesis and proliferation 52. 
There are 2 isomers of transcription factor Hif1, α and β, which dimerize for transcriptional 
activity 53. Studies have shown high activity of Hif1α in the regulation of vasculogenesis, 
and that reduced levels of Hif1α impairs normal development of the coronary arteries 52-54. 
Wilms tumor-1 (Wt1) is a downstream target of Hif1α and plays an important role in 
coronary artery formation, as a key regulator in the formation of the PEO and epicardial 
cells 55, 56. It has been demonstrated that knock out of Wt1 gene in epicardial cells results 
in loss of coronary artery development and fetal lethality between E16.5 to E18.5 57. 
Expression of Wt1 results in activation of Snail1 and Slug. It has also been shown that 
expression of Slug is detected in the PEO, epicardial, epithelial as well as mesenchymal 
cells 58. While Snail1 expression is also present in the epicardial and subepicardial cells at 
E10.5-12.5, but not expressed in the PEO 59.  Both Snail1 and Slug repress the expression 
of a cell adhesion protein, E-cadherin, to promote EMT as well as cell migration 52. TGFß 
also plays a role in EMT by also activating Snail1 60. Retinoic acid (RA), the active 
derivative of vitamin A, also plays an important role in coronary artery development. RA 
signaling promotes epicardial EMT, EPDC differentiation, and cardiomyocyte 
proliferation through the activation of basic fibroblast growth factor (bFGF) secretion from 
the myocardium 61, 62. Retinaldehyde dehydrogenase (RALDH2 or ALDH1a2) is the 
enzyme that catalyzes a critical step in RA production. Studies have shown that Wt1 
regulates epicardial expression of ALDH1a2 63, 64 in the regulation of coronary 
vasculogenesis in mice 65. Thus, RA is an important regulator of myocardial growth and 
vascular development of cardiac progenitors in the heart. 
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The origin of endothelial cells of the coronary vasculature has been controversial 
in the past; however, it has been generally established that these cells originate from many 
populations of precursor cells. Some endothelial cells originate from PEO EPDCs, 
angiogenic sprouts of the sinus venosus, and some from the ventricular endocardium 66-68. 
As endothelial progenitors continue to proliferate, by E16.5 a coronary vascular plexus is 
formed. 
1.2 Congenital Heart Defects and Coronary Artery Defects 
1.2.1 Genetic and Environmental Basis of Congenital Heart Defects 
Impairment of cardiogenesis can be caused by inherited or non-inherited factors 69, 
70. Inherited factors are considered chromosomal disorders such as Down syndrome, 
Mendelian syndrome, and non-syndromal single gene mutations. Chromosomal disorders 
account of 8-10% of CHDs, while Mendelian syndrome accounts for 3 to 5% of CHDs 70, 
71. The other 85% of CHDs still remains unknown and are attributed to non-inherited 
factors, such as environmental factors that contribute to increasing the risk of CHDs. 
Environmental risk factors include maternal cigarette smoking, maternal alcohol 
consumption, or pregestational diabetes, to name only a few 72.  
1.2.2 Septal Defects 
1.2.2.1 Atrial Septal Defects 
Atrial septal defects (ASD) occur when the septum between the right and left atria 
fails to correctly form. This creates a shunt for blood between the atrial chambers. ASD is 
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a common type of CHD with a prevalence of 1.6 per 1000 live births 73. ASDs can occur 
in either the septum primum or septum secundum. ASD of the septum primum occurs from 
fusion failure of the septum primum to the endocardial cushion. This defect may result 
from decreased cell proliferation of the septum primum or abnormal development of the 
endocardial cushion 74. ASD of the septum secundum results from a failure to close the 
foramen ovale, which may occur due to inadequate growth of septum secundum or an 
excess of apoptosis in the septum primum. Too much apoptosis in the septum primum can 
result in an oversized foramen secundum, unable to be covered by the septum secundum. 
Studies have demonstrated that molecular interaction of Gata4, Nkx2.5 and Tbx5 are 
necessary for atrial septum formation, and mutations in these are associated with ASD 
secundum defects75-77. 
1.2.2.2 Ventricular Septal Defect 
The ventricular septum is composed of five parts which include, the membranous, 
muscular, infundibular, atrioventricular, and the inlet. If development or fusion of any one 
of these components fails to occur during cardiogenesis it will result in a VSD in the 
corresponding component. VSDs create a shunt between the right and left ventricles 78. 
There are many different classifications due to the different anatomic locations and 
histologic variations of VSDs, which have been separated into four major categories 78. 
Type 1: infundibular, which is located in the outlet septum of the right ventricle just beneath 
the semilunar valves. Type 2: membranous, located in the membranous septum below the 
crista supraventricularis. Membranous VSDs are the most common and account for 80% 
of all defects. Type 3: inlet or atrioventricular, located within the inlet of the right 
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ventricular septum, just below the tricuspid and mitral valves. Type 3 VSDs are largely 
found in patients with Down syndrome, and account for 8% of defects 78. Type 4: muscular, 
which is located in the muscular septum, the opening is bordered by muscle of ventricular 
septum in the apical, central and outlet parts. The size and location of the VSD will 
determine the amount of blood being shunted between chambers as well as the direction of 
blood flow 78. VSDs are often isolated, but can occur in association with other CHDs such 
as ASDs, patent ductus arteriosus, and pulmonary stenosis. Different genetic factors 
including chromosomal, single gene and polygenic inheritance have been identified to 
increase the incidence of VSDs. It has been reported VSDs are associated with mutations 
in Nkx2.5 and Gata4 genes 79-82. Non-inherited risk factors include maternal infection, 
pregestational diabetes, and exposure to toxins such as alcohol, marijuana, and 
metronidazole 78. 
1.2.2.3 Atrioventricular Septal Defect 
Atrioventricular septal defect (AVSD) is the presence of an ASD at the site of 
ostium primum, along with a membranous VSD 83. This defect occurs when there is failure 
of formation of the endocardial cushions. The endocardial cushions separate the heart near 
the AV valves, which separate the atria from the ventricles. AVSDs have a prevalence of 
0.24-0.31 per 1000 live births, and have a 48% postnatal mortality rate 84-86. Down 
syndrome is a chromosomal abnormality that increases the risk of AVSD, with an 
incidence of 17% in neonates 87, 88. Nkx2.5, Gata4, and Tbx5 are genes known to be 
involved in the development non-syndromic AVSDs 89-92. 
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1.2.3 Valve Defects 
Valve stenosis occurs when the valve leaflets appear thickened due to lack of 
remodeling during development, and the valve commissures may be partially fused 93. 
Thickened valves will cause outflow obstruction, leading to increased pressure in the 
corresponding ventricle. Increased intracavitary pressure can lead to ventricular 
hypertrophy, and ultimately to ventricular dysfunction 93. Pulmonary valve stenosis occurs 
in 8-10% of patients with CHDs, and aortic valve stenosis occurs in 3-8% 94. Aortic valve 
stenosis is 4 times more likely to occur in males than females, while pulmonary valve 
stenosis has a slight female predominance 93. The combination of both pulmonary and 
aortic valve stenosis in the same patient is very uncommon 94. Though, both valve defects 
have been linked to LEOPARD syndrome, in which there is a higher risk of both occurring 
93. 
1.2.4 Outflow Tract Defects 
1.2.4.1 Double Outlet Right Ventricle 
Double outlet right ventricle (DORV) occurs when there is a disturbance during 
remodeling of the OFT. With a DORV, the aorta, instead of being connected to the left 
ventricle, it is connected to the right ventricle. With this type of defect, both the aorta and 
the pulmonary artery have a connection to the right ventricle. An essential VSD is also 
present for circulation of blood between the left and right chambers. It is estimated that the 
incidence of DORV is 1.6 per 1000 live births 95. In 15% of DORV patients, a mutation 
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was identified in the Gata4 cofactor, Fog2 96. Chromosomal abnormalities such as Down 
Syndrome are associated with a small percentage of DORV patients 70, 97.  
1.2.4.2 Truncus Arteriosus 
Truncus arteriosus, also known as the common trunk, occurs when division of the 
OFT into the aorta and pulmonary artery fails to occur during development. This results in 
one common artery that arises from the left and right ventricle. Truncus arteriosus occurs 
in approximately 1% of children born with a CHDs. Approximately 50% of patients with 
truncus arteriosus are associated with chromosome 22q11.2 deletion syndrome 98, 99. 
Complete repair of truncus arteriosus is not always possible; truncus arteriosus is 
considered the most severe type of OFT defect. 
1.2.4.3 Pulmonary Artery Stenosis 
When there is narrowing or constriction of the pulmonary artery vessel, pulmonary 
artery stenosis occurs. This will increase the resistance in the pulmonary artery, leading to 
increased pressure in the right ventricle, which may subsequently lead to right ventricle 
hypertrophy 100. Pulmonary artery stenosis is often associated with a deletion of a portion 
of chromosome 7, as is known in Williams syndrome. Pulmonary artery stenosis can be 
treated with balloon dilation, stent placement or surgical repair 101. 
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1.2.5 Myocardial Defects 
1.2.5.1 Ventricular Hypertrophy 
Ventricular hypertrophy is the enlargement or thickening of the ventricle walls. 
This occurs physiologically when there is increased pressure in the ventricle, forcing the 
muscle to work harder. This increased pressure can be caused by a number of different 
factors including other associated cardiac structure defects. Cardiac hypertrophy can also 
be instigated by genetic syndromes such as, Noonan syndrome and Costello syndrome, and 
metabolic diseases, such as long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and 
adenosine triphosphate synthase deficiency, maternal diabetes mellitus, and steroid use 102. 
TGF-	𝛽1, a gene necessary for cardiac development, and transgenic mice overexpressing 
TGF-	𝛽1, have cardiac hypertrophy. 𝛽-MHC is expressed from early stages in development 
and is traditionally recognized for its role in force development 103. 𝛽-MHC can also be 
used a marker of cardiac hypertrophy and can be induced by disease-related hypertrophic 
stimuli in rat cardiomyocytes. 104. TGF-	𝛽1 may play a role in the pathogenesis of cardiac 
remodeling induced by maternal nicotine exposure in rat offspring 105. Acting as a 
secondary messenger for many signaling molecules, such as TGF-	𝛽1, abnormal levels of 
reactive oxygen species (ROS) are also able to induce hypertrophic pathways within 
cardiomyocytes via MAPKs, PKC, and Src 106. 
It is important to note that the right and left ventricles have different embryologic 
origins, as the right ventricle originates from the SHF and the left ventricle from the FHF. 
In the adult, the right ventricle is a low-pressure chamber, as it faces low resistance from 
the pulmonary circulation. The right ventricle walls are generally thinner compared to the 
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left ventricle, which has thicker walls designed to handle higher pressure. This is important 
to note, as the mechanism of ventricular hypertrophy can be different between the right and 
the left ventricles, though markers such as TGF-	𝛽1 and 𝛽-MHC may be the same. The 
mechanisms of how each occur independently has not been extensively studied 106. 
1.2.5.2 Isolated Hypoplastic Left Ventricle 
Isolated hypoplastic left ventricle (IHLV) is a congenital heart defect where the left 
ventricle does not form correctly during development. IHLV is an independent and isolated 
underdevelopment of the left ventricle chamber. It is worth noting that IHLV is not 
associated with other defects such as mitral and aortic valve underdevelopment, and ASD 
that are normally associated with the related congenital defect, hypoplastic left heart 
syndrome. IHLV does not allow proper function of the heart, as the left ventricle is unable 
to fill or pump blood properly. In utero, this problem can be bypassed due to the ductus 
arteriosus, but after birth when the ductus arteriosus closes, major problems arise as it 
becomes extremely difficult to get oxygen-rich blood into the systemic circulation. If 
untreated with surgical intervention, the prognosis for the infant is death 107.  
1.2.6 Coronary Artery Defects 
1.2.6.1 Hypoplastic Coronary Artery Disease 
Hypoplastic coronary artery disease refers to a congenital abnormality where the 
coronary arteries are atypically small, or underdeveloped. This is identified by a marked 
decrease in the luminal diameter and/or length of one or both of the major branches 108. 
This condition can severely impair heart function as the cardiac muscle is unable to receive 
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sufficient blood supply and it is highly associated with sudden cardiac death 109-111. About 
1% of patients undergoing coronary angiography have a congenital coronary anomaly 109. 
Coronary artery abnormalities can easily go unrecognized as many of these patients do not 
show signs, symptoms, or complications. Sudden cardiac death has been reported as the 
initial presentation of this hypoplastic coronary artery condition in the majority of patients, 
and because of this, opportunities for treatment are rare. However, some of the cases are 
associated with myocardial ischemia, and other related consequences such as angina, 
infarction, and arrhythmias. One in 7.4 of people die of sudden cardiac death, and 75% of 
cases of sudden cardiac death are attributed to coronary heart disease 112. Congenital 
coronary artery anomalies contribute to a proportion of these sudden cardiac death patients. 
In young American athletes, coronary artery anomalies are the second leading cause of 
exercise-related sudden cardiac death, second to hypertrophic cardiomyopathy 109. There 
is limited knowledge on the genetic or environmental conditions that result in hypoplastic 
coronary arteries. Although, studies in neonatal mice have shown that a deficiency in NO 
release from eNOS during heart development lowers Wt1 and Gata4 transcript levels and 
results in the formation of hypoplastic coronary arteries and consequently myocardial 
infarction 113.  
1.3 Maternal Nicotine Exposure 
1.3.1 Cigarette Smoking During Pregnancy  
There are many proposed risk factors for the development of CHDs, and cigarette 
smoking during pregnancy is one of them. Cigarette smoke is composed of a mixture of 
over 4700 chemical compounds including many free radicals and oxidants 114. Cigarette 
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smoking during pregnancy significantly increases the risk for the development of CHDs in 
the offspring 115. Maternal cigarette smoking is one of the most significant causes of 
preventable perinatal morbidity and mortality worldwide 116. There is a dose-response 
relationship between cigarette smoking and the risk for all CHDs as a group 115. How 
tobacco smoke affects fetal development has been examined extensively in humans. Many 
of the 4700 chemicals can cross the placental barrier and have a direct harmful effect on 
the developing fetus 117. A significant number of women still smoke during pregnancy, 12-
15% between the U.S., U.K., and Australia 118. In Canada, around 75000 newborns are 
exposed to maternal smoke each year, and in Northwest Territories, rates are as high as 
59% 119, 120. Despite knowing the detrimental effects of smoking, pregnant or non-pregnant 
women have a difficult time quitting due to the highly addictive nature of nicotine. Only 
46-54% of pregnant women successfully abstain from smoking during pregnancy 121, 122. 
With the goal of reducing the prevalence of maternal smoking during pregnancy, resources 
are available to help smoking cessation. According to the Society of Obstetricians and 
Gynaecologists of Canada (SOGC) Clinical Practice Guidelines regarding nicotine use in 
pregnancy, “smoking cessation counselling should be considered as a first-line intervention 
for pregnant smokers. Nicotine replacement therapy and/or pharmacotherapy can be 
considered if counselling is not successful.” 123. Psychosocial strategies such as counseling, 
and cognitive and behavioural therapy can be effective. If counselling is unsuccessful, 
pharmacotherapies such as NRTs should be considered, as they are recognised to be 
beneficial to those highly addicted 118, 123, 124. Women are offered NRTs after unsuccessful 
counselling and provided with sufficient information regarding the known risks during 
pregnancy 123, 125-127. Current evidence in the literature is lacking to properly assess whether 
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the risks of NRTs as a pharmacotherapy for pregnant women outweigh the benefits 128. The 
link between NRTs and congenital anomalies is poor and needs to improve to elucidate the 
safety concerns surrounding fetal development 123, 126, 129, 130. Women who smoke and 
become pregnant are recommended NRTs based on convincing research for their 
effectiveness as an aid in smoking cessation 131. However, there remains the critical 
question, are these replacements risk free? 
1.3.2 Nicotine Replacement Therapies 
NRTs are products which aid in smoking cessation by easing the transition from 
cigarette smoking to abstinence. NRTs aim to decrease the strength of craving and 
withdrawal symptoms. NRTs can either be over-the-counter or prescribed, they vary in the 
dose of nicotine, and how nicotine is administered. Types of NRTs include: nicotine patch, 
gum, lozenges, nasal spray, and inhaler. There is clear evidence to support the effectiveness 
of NRTs to aid in smoking cessation and to support their use in the general public 132. 
Though, NRT safety during pregnancy has not been extensively evaluated 133. 
Alternatively, electronic cigarettes (e-cigarettes) have become a popular smoking cessation 
tool, and recently have become more available, due to extensive marketing 134. E-cigarettes 
also contain other ingredients such as diacetyl, vegetable glycerin and propylene glycol, 
which independently cause many harmful effects 135. Moreover, the use of e-cigarettes has 
been increasing rapidly (5-7%) in young adults of reproductive age (20-28), regardless of 
a history of previous cigarette use 136, 137. NRTs and e-cigarettes are perceived to be a safe 
alternative to cigarette smoking because they do not contain many of the harmful toxins 
found in tobacco smoke, although, these products contain nicotine, and the effects of 
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nicotine on the developing fetus are not well known. It is postulated that the perception of 
NRTs and e-cigarettes being safer during pregnancy may actually result in pregnant women 
using these tools more freely and frequently. As nicotine itself has been demonstrated to 
have detrimental effects during development, this could cause even greater harm to the 
fetus because of the elevated and uncontrolled levels of nicotine 138. Currently, there is no 
consensus on whether NRTs should be recommended during pregnancy due to persistence 
concerns about safety for the developing fetus 139. 
The use of nicotine reduces the woman’s ability to get pregnant (fecundity rate), in 
a dose-dependent manner. It has also been shown that pregnant smokers have a 33% higher 
risk of spontaneous abortions (fetal loss before 20 weeks in humans) 140. For these reasons, 
the effects of maternal nicotine exposure (MNE) must be investigated to discover the 
impacts on embryogenesis. 
1.3.3 Nicotine 
Nicotine is one of the most potent and toxic alkaloids found in the tobacco plant 
leaf. It is known to have serious systemic side effects in addition to being highly addictive 
141. Nicotine, 3-(1-methyl-2-pyrrolidinyl) pyridine (C10H14N2, Figure 3), is a tertiary amine, 
bicyclic compound, composed of both a pyridine and pyrrolidine ring, which exists in 
tobacco as 2 enantiomers, levoratary (S, -) and dextro (R, +), with the S (-) being the 




Figure 3. Structure of nicotine. 
 
Exogenous nicotine acts as an agonist by stereo-selectively binding to the nicotinic 
acetylcholine receptors (nAChRs) stimulating the central and peripheral nervous systems. 
In smokers, the nAChR binding capacity of nicotine is increased, which is caused by a 
higher number of nAChRs in the brain of smokers 142. The nAChR is a pentamer made of 
5 subunits that coassemble to form a functional non-selective cation channel. There are 17 
different types of nAChR subunits (α 1-10, β 1-4, γ, δ, ε) which creates a potential to have 
many different nAChRs. Many nicotinic receptor subunits have been identified and various 
combinations of these subunits produce functional nAChR subtypes with distinct 
pharmacological properties 143. Nicotine has higher affinity binding to specific subunit 
combinations. For example, nAChR located in the brain have exceptionally high-binding 
affinity for nicotine, which is the reason for nicotine addiction associated with over 4 
million worldwide smoking-related deaths each year 144. Whereas, nAChR at the 
neuromuscular junction (NMJ) have extremely low binding affinity for nicotine. If nicotine 
were able to activate the nAChR located at the NMJ as strongly as it does in the brain, 
nicotine exposure would cause intolerable, painful and possibly fatal muscle contractions 
144. The majority of high affinity nAChRs are heteromeric and consist of a combination of 
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α and β subunits. α4β2 nAChR in the brain are such high affinity receptors for nicotine and 
are thought to underlie nicotine addiction.  
Nicotine acts via 3 major mechanisms, producing physiological and pathological 
effects on many organ systems: ganglionic transmission, nAChRs via catecholamines, and 
central nervous system stimulation of nAChRs 141. As nicotine is ingested and gets into 
arterial circulation, it quickly travels to the brain. Nicotine readily diffuses into the brain 
tissue and binds to nAChRs. The receptor channel will open, allowing in an influx of 
sodium and calcium ions, which are capable of further activating voltage-dependent 
calcium channels, resulting in further calcium entry 145.  
Nicotine is a sympathomimetic drug that stimulates the release of catecholamines, 
such as dopamine and norepinephrine, in the brain, and by activation of nAChR localized 
on peripheral postganglionic sympathetic nerve ending and in the adrenal medulla 145, 146. 
Activation of nicotinic receptors produce a wide variety of acute and long-term effects on 
organ systems, cell proliferation and apoptosis throughout the body. Nicotine can cause an 
increase in plasma free fatty acids, hyperglycemia, reduce sensitivity to insulin, and may 
contribute to endothelial dysfunction 145. Specifically, nicotine increases heart rate and 
myocardial contractility, transiently increases blood pressure, and causes constriction of 
the coronary blood vessels, causing a decrease in blood flow to the heart. The 
cardiovascular effects of nicotine are exerted directly through stimulation of the 
acetylcholine receptors 140. It is not entirely clear, which subtype(s) are responsible for the 
regulation of cardiovascular function. Although, it is believed that the α3β4 nAChR is 
responsible for mediating the cardiovascular effects of nicotine 145. It has also been 
demonstrated that nAChRs that mediate an initial decrease in heart rate probably contain 
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𝛼7 subunits, whereas 𝛽4 subunits have a role in mediating the subsequent increase in heart 
rate 143. Some health concerns from long-term nicotine exposure include cardiovascular 
disease, delayed wound healing, cancer, and reproductive disorders 145. Reactive oxygen 
species (ROS) are very abundant among the many harmful toxins released from cigarette 
smoke, and have been linked to several adverse effects of smoking. Nicotine being a major 
component of cigarette smoke, has been demonstrated to induce harmful levels of oxidative 
stress as well. 
Nicotine is lipid-soluble and therefore quickly travels into the intracellular space 
from the plasma. Nicotine is metabolized by the liver to 6 primary metabolites, and 
eliminated by the kidney. Twenty metabolites of nicotine have been identified, though all 
are thought to be less active than nicotine itself 140. Quantitatively, the most important 
metabolite is the lactam derivative cotinine. In humans, about 70 to 80% of nicotine is 
converted to cotinine 147. The enzyme CYP2A6 is primarily responsible for the oxidation 
of nicotine and cotinine. The plasma half-life of nicotine averages about 2 hours, while 
cotinine has a half-life of about 12 hours and serum concentration levels have been 
demonstrated to be 10-fold higher than nicotine147. Cotinine is able to bind to nAChRs but 
has little effects on cognitive performance and no cardiovascular effects in humans 148, 149. 
Because of the long half-life, and higher serum concentration of cotinine, it is frequently 
used as a biomarker for nicotine, and for measurements nicotine exposure 150. 
Genetic polymorphisms in CYP2A6 activity have been associated with racial 
differences and vast individual variability in the nicotine metabolism rate 145. On average 
Caucasians and Hispanics metabolize nicotine more quickly than Asians and African 
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Americans. Among women, the rate of nicotine metabolism is fast in women taking oral 
contraceptive and even faster in women who are pregnant, compared to other women 145. 
1.3.4 Fetal Nicotine Exposure 
Nicotine and nicotine metabolites are able to easily cross the chorioamniotic 
membrane and enter into fetal circulation where it interacts with nAChRs in the fetal brain 
151. Indeed, the low pH of the amniotic fluid favors the accumulation of nicotine and its 
metabolites in the fetus 152. For this reason, fetal nicotine concentrations are generally 15% 
higher than that of the maternal serum 140, 152. One study actually found that mid-trimester 
nicotine concentrations in amniotic fluid were 54% higher compared to maternal serum 
levels. The same study showed that at the time of delivery, concentration of nicotine in 
umbilical vein serum/maternal serum ratio was 1.12 ± 0.3 140. This accumulation in the 
amniotic fluid may play a major role in teratogenesis in the embryo 153. It is also important 
to note that nicotine is able to bind and activate the nAChRs which are present in the 
placenta. This indirect effect of nicotine can lead to vasoconstriction in the placenta and 
subsequent hypoxia, leading to elevated ROS in the developing fetus 154. Nicotine not only 
accumulates in placental tissue, amniotic fluid, and fetal blood, but also in breast milk, 
leading to not only significant fetal exposure, but significant neonatal exposure as well 140, 
151, 155. 
Nicotine affects each trimester of pregnancy. The risk of spontaneous abortion in 
the first trimester is increased with nicotine exposure, and in the third trimester there is an 
increased risk of premature delivery and decreased birth weight. Nicotine has been 
demonstrated to affect birth weight by influencing the 2 determining factors: the gestational 
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age at the time of delivery, as well as the fetal growth rate 140. Nicotine has also been shown 
in animal models and humans to increase maternal blood pressure and heart rate as well as 
reduce the uterine blood flow 140. 
1.3.5 Effects of Nicotine on Fetal Development 
Maternal nicotine exposure (MNE) is a major public health concern, as nicotine is 
harmful to the developing fetus. Pregnancies that are complicated by MNE are significantly 
more likely to have adverse outcomes 156. Adverse pregnancy outcomes that are associated 
with MNE include: prematurity, intrauterine growth restriction, premature rupture of the 
membranes, preterm labor, placental abruption, fetal demise, and placenta previa 140. MNE 
is also associated with many neonatal and childhood complications including: low birth 
weight, sudden infant death syndrome, asthma, lower IQ, smaller head circumference, 
behavioural problems, attention deficit disorder, and upper respiratory infections 140. 
Children that are exposed to nicotine in utero have a higher risk of developing health 
problems such as, impaired function of the endocrine, cardiovascular, respiratory, 
reproductive, and neurologic systems 156.  
MNE has specifically been demonstrated to have many adverse effects in various 
fetal organs during development, including the lungs, kidney, pancreas, and heart to name 
a few. MNE exacerbates neonatal hyperoxia-induced lung fibrosis 157, induces neonatal 
kidney fibrosis 158, causes pancreatic mitochondrial dysfunction159, and impairs placental 
structure and function 160. These are only a few examples of the many harmful effects of 
nicotine on the developing embryo. Specifically in the fetal heart, nicotine has been shown 
to alter the cardiac conduction system 161, induce fetal arrhythmia, reduce fetal blood 
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pO2 levels and oxygen saturation, and increase fetal arterial blood pressure 162. Transgenic 
mice lacking 𝛽2 containing nAChRs exhibit deficits associated with MNE; such as, growth 
restriction, unstable breathing, and catecholamine biosynthesis 163. This may indicate that 
mechanisms of nicotine’s side effects involved loss of function of nAChRs subtypes, 
possibly via activity-dependent desensitization 163. Many of the adverse effects of MNE in 
the fetus seem to be caused by the combined effects of impaired placental perfusion, and 
direct action on the cardiovascular system 164. Numerous studies have demonstrated that 
fetal exposure to nicotine increases levels of oxidative stress in various fetal organs, a likely 
mechanism for these detrimental effects 165, 166. Nicotine affects embryonic development 
in a concentration-dependent manner. The nicotine-induced embryonic malformations are 
also, in part, a result of excessive cell death. Nicotine increases [Ca2+]i and levels of reactive 
oxygen species (ROS), which play a role in nicotine-induced embryonic apoptosis and 
malformations 153. This MNE-induced increase in oxidative stress in the fetus has been 
shown to have effects on the fetal heart. Increased levels of oxidative stress have been 
demonstrated to play a casual role in nicotine-induced developmental programming of 
ischemic sensitive phenotype in the fetus 167. MNE also results in fetal programming of 
vascular oxidative stress in the offspring. This vascular dysfunction is thought to be 
mediated by ROS as well as decreased superoxide dismutase activity 133. The heart is 
arguably the most important organ, particularly during embryonic development and CHDs 
are considered to be the most serious birth defect. Of our knowledge, to date, there is no 
report on the effects of MNE during pregnancy on the development of CHDs in fetuses. 
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1.4 ROS  
1.4.1 ROS Regulation in Growth and Development 
Maintaining a balance between oxidants and antioxidants is important for any living 
system, and a shift in balance could result in accumulation of reactive oxygen species 
(ROS) that further generates oxidative stress 168. ROS refer to the derivatives of oxygen 
free radicals that are produced from different cellular sources under physiological or 
pathophysiological conditions 169. ROS result from many endogenous and exogenous 
sources, such as inflammatory cells, radiation, smoking, etc. and are believed to be the 
underlying cause for many disorders 168. ROS can mediate a variety of fundamental cellular 
processes such as proliferation, differentiation, migration and apoptosis 48. It has been 
suggested that the levels of ROS release determine the cell’s response, indicating that ROS 
functions as a classical signaling molecule. For example, basal levels of ROS mediate 
expression of genes required for differentiation 170 or proliferation 171, 172. Whilst, an 
increase in ROS above basal levels induces processes that are harmful for cell survival such 
as lipid peroxidation and oxidative modifications of various proteins and RNA 173. These 
modifications to RNA can result in disturbances of translation and impairment of protein 
synthesis 174. Excess ROS during embryonic development can also induce cellular 
apoptosis and can be detrimental to embryonic growth 175-177. Increased levels of ROS in 
cardiomyocytes specifically can affect many different cardiomyocyte functions. ROS can 
target key molecular regulators such as MAPK, PKC and Scr proteins stimulating pro-
hypertrophic pathways 106. 
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1.4.2 Chemistry of ROS 
ROS includes superoxide anion (O2-·), hydroxyl radical (HO·) and hydrogen 
peroxide (H2O2), which are mainly produced from: i) mitochondria respiratory mechanism, 
ii) NADPH oxidases, and iii) enzymatic activities such as xanthine oxidase and cytochrome 
p450 178. Superoxide anion is considered a primary ROS and can either be generated from 
a metabolic process or by activation of oxygen by irradiation. Via an enzyme or metal 
catalyzed process, these primary ROS will react with other molecules to generate 
secondary ROS. Generated O2-· undergo a dismutation reaction in the presence of a 
superoxide dismutase (SOD) enzyme, converting it into hydrogen peroxide and oxygen 
(Figure 4a) 168. However, hydrogen peroxide that is produced in the cell is dangerous as it 
can easily be converted into hydroxyl radical OH· 174. Closely linked with the generation of 
free radicals is redox active metals. An iron redox couple is associated with the redox state 
of the cell, and is kept under strict physiological control. In conditions of excessive stress, 
and excess O2-· release, free iron from enzymes that is released takes part in Fenton’s 
reaction (Figure 4b), which promotes the generation of secondary ROS, hydroxyl radicals.  
OH· is one of the most destructive free radicals when interacting with Fe2+, because they are 
extremely reactive 174. Hydroxyl radicals produced in close proximity to DNA or RNA can 
react, resulting in mutations or modifications. Over 20 different types of RNA base damage 
have been identified, 8-hydroxyguanosine (8-OHG) being the most prevalent oxidized base 
(Figure 4c) 174. The hydroxyl radical reacts with the guanine to form C8-OH adduct radical, 
as it is highly reactive. Next, 8-OHG is generated from the loss of an electron (e−) and 
proton (H+) 174. Oxidative modification of mRNA affects translation, which consequently 
reduces protein production, though the mechanism of how oxidized bases on mRNA affect 
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translation needs further exploration 174. The hydroxyl radicals can also react with 
polyunsaturated fatty acid residues of phospholipids, the main component of the cell 






Figure 4. Chemistry of ROS 
Superoxide anion (O2-·) undergo a dismutation reaction in the presence of a superoxide 
dismutase (SOD) enzyme, converting it into hydrogen peroxide (H2O2 ) and oxygen 
(Figure 4a). Hydrogen peroxide is then converted to secondary ROS, being hydroxyl 
radical (OH•), by Fenton’s reaction (Figure 4b). Hydroxyl radicals are capable of 
promoting the oxidation of guanosine to 8-hydroxyguanosine (Figure 4c). The 
hydroxyl radical is also able to react with polyunsaturated fatty acid residues of 
phospholipids, which are highly sensitive to oxidation, resulting in lipid peroxidation 







Specifically, many of the proteins and molecules that are needed for proper heart 
development are oxidized with an increase in ROS levels 179. Because of this, elevated ROS 
levels have been shown to contribute to the development of CHDs, and coronary artery 
defects (CADs) in the offspring of mice 180. 
1.4.3 Nicotine Induced ROS 
Nicotine exposure increases levels of oxidative stress, which is known to have 
detrimental effects in the body. As discussed above, binding of nicotine to the nAChR 
allows an influx of Ca2+. Extended stimulation of this receptor is able to further increase 
cytosolic Ca2+ levels beyond basal levels. Nicotine exposure has been demonstrated to 
increase cytosolic Ca2+ levels, leading to a decrease in mitochondrial enzyme (pyruvate 
dehydrogenase, alpha-ketoglutarate dehydrogenase, malate dehydrogenase) activities, 
which may contribute to increased mitochondrial ROS production through increased Ca2+ 
flow into the mitochondria. Nicotine has also been demonstrated to mediate intracellular 
Ca2+ fluxes and activate protein kinase C, which in turn is capable of activating NADPH 
oxidase 1 that leads to mitochondrial oxidative stress. This, in turn, produces 
malondialehyde and nitric oxide with an associated decrease in antioxidative enzymes and 
glutathione activity levels, leading to a loss of mitochondrial membrane potential 181. The 
underlying mechanisms and toxicological effects of nicotine-induced mitochondrial 
dysfunction is still not fully described.  
Other studies have demonstrated that nicotine induced ROS leads to activation of 
nuclear transcription factor κB (NF- κB), a redox-sensitive transcription factor 182. NF- κB 
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has been shown to be involved in biological processes such as development, apoptosis, and 
inflammation 114.  
1.5 Rationale and Hypothesis 
Maternal cigarette smoking during pregnancy is a known risk factor for CHDs in 
the offspring 115. Maternal cigarette smoking has been shown to increase the incidence of 
CHDs, such as septal and right-sided obstructive defects, in the offspring. There is 
increasing evidence that MNE alone can have many serious consequences to the 
developing fetus. Nicotine-induced oxidative stress is a proposed mechanism for many of 
the harmful effects on the embryo 165, 166. Oxidative stress in the fetal heart has been 
demonstrated to contribute to the development of congenital heart defects and coronary 
artery defects 183. Because of this, it was hypothesized that maternal nicotine exposure 
(MNE) during pregnancy impairs embryonic heart development leading to congenital 
heart defects and coronary artery defects in the offspring of mice. 
1.5.1 Study Aims 
1. Determine if MNE results in a significantly higher rate of CHDs compared to the 
control, and to characterize the spectrum of these cardiac anomalies. 
2. Determine if MNE attenuates coronary artery development and results in 
hypoplastic coronary arteries. 





Chapter 2  
2 Materials and Methods 
2.1 Animals 
This study utilized mice in accordance with the Guide to Care and Use of Animals 
of the Canadian Council of Animal Care. The study protocol was approved by the Animal 
Care Committee at Western University, Canada. C57Bl/6 mice were purchased from 
Jackson Laboratory (Bar Harbor, Maine). Females at 8 to 10 weeks of age, had osmotic 
pumps (Alzet #2004, Cupertino, CA, USA) implanted subcutaneously, releasing a dose of 
nicotine at 1.5 mg/kg/day. This dose mimics a light smoker, of 1-10 cigarettes per day 184. 
Fourteen days after implantation of the pump, the females were bred overnight in cages 
with healthy males, then returned to their original cage in the morning. The presence of a 
vaginal plug indicated embryonic day (E) 0.5. Females that experienced an unsuccessful 
pregnancy following the presence of the plug were bred again with males. After 2 
unsuccessful pregnancies, females were sacrificed and not included in analysis.  
Embryos from pregnant mice were collected at E10.5, E12.5 and E18.5 via 
caesarean section for experiments and analysis (Figure 5). The dam was sacrificed by 
cervical dislocation after collection was complete. There were 2 groups: control (Ctrl) and 
maternal nicotine exposure (MNE). To analyze mRNA and oxidative stress during 
embryonic development, dams were sacrificed at E10.5. Fetal hearts were collected and 




Figure 5. Study design timeline 
Nicotine-filled Alzet osmotic pumps were implanted on C57Bl/6 female mice 14 days 
prior to breeding with a normal male mouse. Fetal hearts were collected on E10.5 for 
qPCR and oxidative stress analysis, and E18.5 for qPCR and morphological analysis. Red 
markers indicate MNE group; blue marker indicates control mouse hearts collected at 
E12.5 for ex vivo epicardial EMT assay. 
2.2 Osmotic mini pumps  
Alzet (#2004) 28-day osmotic minipumps were prepared 24 hours prior to 
implantation. The online Alzet pump calculator was utilized to determine the correct dose 
to fill the pump with nicotine solution according to the weight of the animal. Nicotine ((-)-
nicotine N3876 Sigma-Aldrich) was diluted in sterile saline and injected into the pump 
ensuring no air bubbles were present. Prepared pumps were left in sterile saline overnight 
at 37	°C and implanted the following day. An intramuscular injection of ketamine (25 
mg/ml), xylazine (2.5 mg/ml), and atropine (30	𝜇g/ml) mixture was used to anesthetize the 
mice for surgical pump implantation. All surgical instruments were wiped clean with 
ethanol followed by sterilization in a bead sterilizer. The incision site was sterilized with 
iodine, a small incision was made on the back of the mouse, and the pump was implanted 
slightly posterior to the scapulae. The incision was closed with silk sutures, with the mice 
monitored throughout recovery. During recovery, the mice were kept warm with a heat 
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lamp until the return of spontaneous movement. Animals were not left unattended until 
they had regained sufficient consciousness to maintain sternal recumbency. Mice were not 
returned to a cage with other animals until fully recovered and incisions were fully sealed. 
2.3 Histological Analysis 
At E18.5, mice were anesthetized with an intramuscular injection mixture of 
ketamine (25 mg/ml), xylazine (2.5 mg/ml), and atropine (30	𝜇g/ml), and the fetuses were 
collected via caesarean section. The head, lower body, limbs and skin of the fetus were 
removed to isolate the thorax. The thoracic cage was immediately fixed in 4% 
paraformaldehyde for 18 to 22 hours at 4 °C. The samples were then dehydrated in ethanol 
and embedded in paraffin to be sectioned, using a microtome, for 5 µm thick serial sections. 
Transverse sections started at the level of the thymus (just above the aortic arch) and 
continued until after the apex of the heart to ensure that the morphology of the heart could 
be analyzed at every level. Heart sections were stained with hematoxylin/eosin (H/E) to 
diagnose CHDs during blinded examination under a light microscope (Zeiss Observer D1, 
Germany). Slides were stained for 5 minutes using Mayer’s Hematoxylin (Thermo Fisher 
Scientific, Waltham, MA, USA), and counterstained for 1 minute with eosin (Thermo 
Fisher Scientific, Waltham, MA, USA). Quantifications of histological images including: 
coronary artery diameter, aortic valve thickness, pulmonary valve thickness, pulmonary 
artery diameter and ventricle wall thickness were performed using ZEN microscope 




Slides with sections that were embedded in paraffin were deparaffinized in xylene 
and then rehydrated. E18.5 fetal heart sections were immunostained using anti-𝛼-smooth 
muscle actin primary antibody (1:3000 dilution, Abcam, Toronto, Canada) to visualize 
coronary arteries. To prevent reactions with endogenous peroxidases, sections were 
blocked in a solution of 0.3% H2O2 diluted in phosphate buffered saline (PBS) prior to 
incubation in secondary antibody 185. The primary antibody was left on overnight at room 
temperature in a humidity chamber. The secondary antibody, biotinylated goat anti-rabbit 
IgG (1:500) (Vector laboratories, Burlington, Canada), was subsequently left on sections 
for 1 hour at room temperature in a humidity chamber. All primary and secondary 
antibodies were diluted in tris-buffered saline with Tween 20 (TBST). Sections were then 
incubated in ABC reagent (1:200 in PBS, Vector Laboratories, Burlington, Canada) for 40 
minutes to amplify the signal, which was visualized using 3-3’ di-aminobenzidine 
tetrahydrochloride (DAB, Sigma-Aldrich, Toronto, Canada) and H2O2. All immunostained 
sections were counterstained with Mayer’s Hematoxylin (Thermo Fisher Scientific, 
Waltham, MA, USA).  
2.5 AMIRA 3D Reconstruction 
AMIRA® software (Template Graphics Software, Thermo Fisher Scientific, 
Waltham, MA, USA) was used to reconstruct E18.5 heart sections into 3-dimensional (3D) 
model representations. Hearts were reconstructed from images taken for each section 25 
µm apart. The 3D reconstructions were used for volumetric measurements, including both 
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CHDs and coronary artery defects (CADs). Sections used for reconstructions of coronary 
vasculature were stained with 𝛼-smooth muscle actin so that coronary arteries could be 
visualized. The compact myocardium, and the right and left ventricles or coronary arteries 
were labeled manually in each section. AMIRA® software calculated the volume of the 
labeled components and those values were used for quantitative analysis of left ventricle 
volume and coronary artery volume in respect to the myocardial volume.  
2.6 Real-time PCR Analysis 
Embryonic E10.5 ventricles were isolated, washed in ice cold PBS, then snap 
frozen in liquid nitrogen. Total RNA was extracted from E10.5 embryonic ventricles using 
the TRIzol reagent method 186. Reverse transcription with M-MLV reverse transcriptase 
(Invitrogen, Canada) was performed using 0.2	µg of total RNA in a reaction mixture 
totaling 20 µl. Following reverse transcription, the resulting cDNA was diluted. Real-time 
quantitative PCR amplification was performed using EvaGreen qPCR MasterMix (Applied 
Biological Materials, Vancouver, Canada) with 2 µl of diluted cDNA mixture for the target 
gene. As for 28S ribosomal RNA, the housekeeping gene, the cDNA was diluted 300 times. 
Primers were designed to amplify the genes Nkx2.5, Gata4, Bmp10, eNOS, Notch1, 
CyclinD1, Hif-1𝛼, Tbx5, Tbx18, Snail1, Slug, 𝛽-MHC, ALDH1a2, bFGF, TGF-𝛽1, Slug, 
BNP, SX and PKCi (Table 1). Eppendorf MasterCycler Realplex (Eppendorf, Hamburg, 
Germany) was used to amplify qPCR mixtures for 35 cycles at temperatures set in 
accordance with the primer melting temperatures. The Ct values of target genes were 




Table 1. Specific primer sequences for real-time PCR analysis 
 
 
2.7 Analysis of Superoxide and Lipid Peroxidation 
Frozen E10.5 hearts from both control and MNE groups were embedded in Tissue-
Tek® O.C.T. Compound (Sakura Finetek USA Inc., Torrance, California, USA) and 
sectioned into 8 µm sections using a cryostat (CM1950, Leica, Wetzlar, Germany). 
Dihydroethidine (DHE, Invitrogen Life Technologies, Burlington, Canada), a molecular 
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probe for superoxide 187, was used to measure relative levels of ROS by quantifying 
fluorescence densitometry. Other sections from corresponding hearts were treated with 
superoxide dismutase before incubation in DHE (2 µM, diluted in PBS) for 30 minutes at 
37 °C in a light protected humidity chamber. Fluorescence was imaged using the 
microscope (Observer D1, Zeiss, Oberkochen, Germany). Three to 5 images were taken 
from 5 different sections per heart sample at a fixed exposure time (50 ms). AxioVision 
Microsoft software (Observer D1, Zeiss, Oberkochen, Germany) was used to quantify the 
densitometry per area of myocardium. 
Lipid peroxidation, another indicator of cellular oxidative stress, was measured in 
E10.5 frozen heart sections. Slides were incubated with anti-4-hydroxynonenal (4-HNE) 
primary antibody (1:300, Applied Biological Materials Inc., Richmond, British Columbia, 
Canada) overnight at room temperature. A fluorescent-labeled donkey anti-goat secondary 
antibody (1:1000, LI-COR Biosciences, Lincoln, Nebraska, USA) was used to visualize 
lipid peroxidation, incubated for 1 hour, and followed by Hoechst stain (1:1000) for 7 
minutes to label the nuclei. Signals were detected using fluorescence microscopy (Observer 
D1, Zeiss, Oberkochen, Germany). Densitometry quantification of the fluorescence signal 
was performed the same way as DHE quantification.   
2.8 Analysis of Cell Proliferation 
Frozen embryonic E10.5 hearts from both control and MNE groups were embedded 
in Tissue-Tek® O.C.T. Compound (Sakura Finetek USA Inc., Torrance, California, USA) 
and sectioned into 8 µm sections using a cryostat (CM1950, Leica, Wetzlar, Germany) and 
mounted on slides. Sections were blocked with 3% goat serum for 45 minutes. Anti-
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phosphorylated histone H3 (pHH3) antibody (1:1000, Abcam) was used for detection 
of phosphorylated histone H3, a marker specific for cells undergoing mitosis. Primary 
antibody was left on for 2 hours at room temperature in a humidity chamber. Sections were 
then incubated for 1 hour in secondary antibody (1:1000, Cy™3-conjugated AffiniPure 
Goat Anti-Rabbit IgG, Jackson Laboratories). Hoescht (1:1000) was used as the nuclear 
stain and was incubated for 7 minutes. The number of proliferating cells were quantified 
from the fluorescence signal. 
2.9 Epicardial EMT Assay 
When embryonic day 12.5 hearts are explanted on a collagen gel, epicardial cells 
grow outward and by about 12 hours, they began to undergo epithelial-to-mesenchymal 
transition (EMT) 188. Collagen (1 mg/ml, type I rat tail collagen, VWR CanLab) was 
solidified to a gel in 24-well plates and hydrated with OPTI-MEM media containing 1% 
FBS and insulin-transferrin-selenium (ITS) for 30 minutes at 37 °C. To determine the effect 
of nicotine on epicardial EMT, ventricles of E12.5 embryos were harvested, cut into 
smaller fragments and plated on the hydrated collagen gel. M199 medium (Sigma-Aldrich, 
St. Louis, MO) was then added to the culture either with or without nicotine (100 ng/ml, (-
)-nicotine N3876 Sigma-Aldrich) After 3 days, images were captured using a phase 
contrast microscope (Observer D1, Zeiss, Germany), and the number of spindle shaped 
cells which had grown outward from the explanted ventricles were quantified. 
2.10 Echocardiography 
  Directly prior to pup collection, fetal heart function was measured at E18.5 using 
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Vevo 2100 system ultrasound with a MS 750 transducer (VisualSonics, Toronto, Ontario). 
Maternal mice were pre-anaesthetized in a chamber, using 3.0% isoflurane. Maternal mice 
were quickly moved from the chamber and secured in the supine position on a heated dock 
(temperature 37 °C) with their noses in a cone used to deliver 0.5-1.5% isoflurane (for 
anesthesia maintenance). An incision was made on the lower abdomen to expose the 
embryotic sacs. Pre-warmed echo gel was placed on the embryotic sacs. The 
echocardiography probe was positioned to obtain a parasternal short-axis view. M-mode 
echocardiography images of the fetal hearts were recorded in the short-axis view. The end 
diastolic left ventricular internal diameter and end systolic left ventricular internal diameter 
were measured. Ejection fraction and fractional shortening were calculated. Mothers were 
then anaesthetized with the ketamine mixture, as above, and removed from isoflurane for 
pup collection. 
2.11 Statistical Analysis 
Data are presented as means ± SEM. Statistical analysis was performed using 
unpaired Student’s t test (GraphPad Prism, version 6.0, La Jolla, CA, USA). A Chi-square 
test was used to analyze the incidence of CHDs and CADs. Two-way analysis of variance 
(ANOVA) followed by Tukey’s multiple comparisons test were used for analysis of both 
CHD and CADs incidence differences between males and females, as well as DHE 
analysis. A P value less than 0.05 was considered statistically significant. 
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Chapter 3  
3 Results 
3.1 Maternal Nicotine Exposure Increases the Incidence of 
Congenital Heart Defects in Mice 
E18.5 hearts of fetuses from mothers exposed to nicotine had many morphological 
abnormalities. Table 2 shows a summary of the spectrum of CHDs seen through the 
examination of control and MNE fetuses. The incidence of CHDs in the E18.5 fetuses of 
dams exposed to nicotine was 41% (P<0.001 compared to control), versus 0% in the 
control group. Defects observed with the highest incidence were left ventricle hypertrophy 
(21%), and atrial septal defect (13%). 
Atrial sepal defects (ASD), and atrioventricular septal defects (AVSD) were 
present in the MNE group, but not in the control group (Figure 6A-D). Pulmonary and 
aortic valves were measured to quantify for valve size (Figure 6E-H). The diameter of the 
pulmonary valve was normalized to the diameter of the pulmonary artery at the level of the 
valve. The area of each aortic leaflet at the thickest section was measured and normalized 
to the area of the aortic orifice. Both the pulmonary valves (P<0.05, Figure 6I) and aortic 
valves (P<0.001, Figure 6J) in the MNE group were significantly thicker when compared 
to the controls. A lower total aortic orifice area was also observed in the MNE group 
compared to the control (P<0.05, Figure 6K). 
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Table 2. The rate of congenital heart defects in the control and MNE fetuses 
 
Data were analyzed using Chi-square test. *P<0.05, **P<0.01, ***P<0.001 vs. untreated 
control. AVSD, atrioventricular septal defect; RV, right ventricle; LV, left ventricle; 





Figure 6. Congenital heart defects in the fetuses of MNE: Septal and valve defects. 
Images labeled (A), (C), (E), and (G) represent normal morphology of heart structures in 
control mice fetuses. MNE induced a wide range of defects including (B) atrial septal 
defect, (D) atrioventricular septal defect; arrows pointing to septum in control and septal 
defect in MNE. (F) thick pulmonary valve, and (H) thick aortic valve; arrows pointing to 
valve leaflets. RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle; PA, 
pulmonary artery; Ao, aorta. (I) PV diameter normalized to PA diameter to quantify for 
thick pulmonary valve. (J) Aortic cusp area normalized to total aortic area to quantify thick 
aortic valve. (K) Area of the aortic orifice opening was measured. Data were analyzed with 
Student’s t-test; *P<0.05, ***P<0.001 vs. untreated control. 
 
Outflow tract defects were also observed in the fetuses of MNE groups, including 
truncus arteriosus and double outlet right ventricle (DORV) (Figure 7A-F). Diameter of 
the pulmonary artery was also measured and was significantly lower compared to the 




Figure 7. Congenital heart defects in the fetuses of MNE: Outflow tract defects.  
Images labeled (A), (C), and (E) represent normal morphology of heart structures in control 
mice fetuses. MNE induced a range of outflow tract defects including (B) pulmonary artery 
stenosis; arrows showing PA diameter measurement; (D) truncus arteriosus, and (F) double 
outlet right ventricle. (G) PA diameter quantification was smaller with MNE compared to 
control. Data were analyzed with Student’s t-test; ***P<0.001 vs. untreated control. RV, 
right ventricle; PA, pulmonary artery; Ao, aorta. 
 
Measurement of thickness of the ventricular myocardium was conducted (Figure 
8A-D). Using the AxioVision 4.8.2 software, the walls of the right and left ventricle were 
measured. Results showed that both right (P<0.01, Figure 8G) and left (P<0.001, Figure 
8H) ventricle wall thickness was significantly higher in the fetuses with MNE compared to 
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those of the controls. Isolated hypoplastic left ventricle (IHLV) was quantified by 
measuring both the area, using AxioVision 4.8.2 software, and volume (Figure 8I), using 
AMIRA® 3D reconstruction, of the left ventricular lumen and normalizing to the total 
myocardium. MNE demonstrated to significantly lower volume (Figure 8J) of the left 
ventricle when compared to the control group, which was independent of myocardial 
volume changes (Figure 8K). 
 
Figure 8. Congenital heart defects in the fetuses of MNE: Myocardial defects. 
Images labeled (A), (C), and (E) represent normal morphology of heart structures in control 
mice fetuses. MNE induced a range of outflow tract defects including (B) right ventricle 
hypertrophy, (D) left ventricle hypertrophy; arrowing showing ventricle wall thickness; 
and (F) AMIRAÒ 3D reconstruction displays isolated hypoplastic left ventricle. (G) right 
ventricle wall thickness. (H) left ventricle wall thickness. (I) left ventricle chamber volume 
normalized to myocardial volume. (J) left ventricle chamber volume. (K) myocardial 
volume. Data were analyzed with Student’s t-test; *P<0.05, **P<0.01, ***P<0.001 vs. 
untreated control. RV, right ventricle; PA, pulmonary artery; Ao, aorta. 
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3.1.1 Effects of Maternal Nicotine Exposure on fetal weight, 
placental weight, and fertility rate 
Sex identification of embryos was performed using PCR analysis for Y 
chromosome specific gene. There were no significant differences in the incidence of CHDs 
between sexes (Figure 9A). 
Fetal and placental weights were recorded at collection. Fetal weight in the MNE 
group was significantly lower when compared to the control (P<0.01, Figure 9B), 
independent of sex. Placental to fetal weight ratio was significantly higher with MNE 
(Figure 9C), independent of sex. Fertility rate (the percent of plugs that resulted in a 
successful pregnancy) was significantly lower with MNE (Figure 9D). The percent of 
absorbed pups was also quantified and was significantly higher in the MNE group at 8.6%, 
compared the control group at 0.7%. 
 
Figure 9. CHD sex ratio, fetal and placental weights, fertility rate. 
(A) Percent of male and female fetuses with or without a CHD, normal n=23, abnormal 
n=26. Data in A were analyzed using Chi-square test. (B) Fetal weight, n=14-29. (C) 
Placental weight, n=14-29. (D) Fertility rate. Data in B and C are mean ± SEM, n=22. 




3.1.2 Maternal Nicotine Exposure Decreases Cardiac Function 
Cardiac function was assessed by echocardiography in E18.5 fetuses. 
Measurements of LV ejection fraction and fractional shortening indicate reduced cardiac 
function in the MNE group compared to the control. LV ejection fraction (EF) was 
significantly lower from 82% to 47%, and fractional shortening (FS) significantly lower 
from 54% to 26% (P <0.01, Figure 10).  
 
Figure 10. MNE impairs cardiac function of fetuses. 
Echocardiography was performed at E18.5 in utero. Measurements of ejection fraction (A) 
and fractional shortening (B). (C) Representative cine-loop images for both control and 
MNE group. MNE was imaged in a different position in order to view left ventricle. Data 
analyzed by Student’s t-test, **P<0.01, ***P<0.001 vs untreated control. LV, left 




3.2 Maternal Nicotine Exposure Increases the Incidence of 
Hypoplastic Coronary Arteries in Mice 
Sections of the fetal heart at E18.5 were stained to identify and evaluate coronary 
arteries. Note that not all control hearts were stained with 𝛼-smooth muscle actin and 
therefore only a portion was used for coronary artery quantification. The incidence of 
coronary artery malformation in MNE fetuses was 31% (Table 3). Fetuses of maternal 
nicotine exposure had lower left and right coronary artery diameter and abundance at E18.5 
(Figure 11A-F, I-K). Impaired coronary artery development is illustrated in three-
dimensional reconstructions of coronary arteries, which demonstrate smaller arteries with 
less 54rborisation in fetuses with MNE (Figure 11G and H). The impaired coronary artery 
development was not simply due to changes in myocardial volume as the ratio of total 
coronary artery volume to myocardial volume was lower in the fetuses of maternal nicotine 
exposed mice at E18.5 (Figure 11L). A combination of CHD and CAD were found in 16% 










Table 4. Incidence of coronary artery defects (CADs) and congenital heart defects 
(CHDs) in E18.5 fetuses 
 
Data were analyzed using Chi-square test. P<0.05, ***P<0.001 vs. control. 
 









Figure 11. Coronary artery defects in the fetuses of MNE. 
Images labeled (A), (C), (E), and (G) represent normal morphology of coronary arteries in 
control mice fetuses. MNE induced a range of coronary artery defects including (B) smaller 
left coronary artery diameter, (D) smaller right coronary artery diameter, (F) lower 
coronary artery abundance; arrows pointing to coronary artery openings; and (H) 
AMIRAÒ 3D reconstruction of coronary arteries displaying a decrease in coronary artery 
abundance. Quantification of left and right coronary artery diameter (I and J respectively), 
abundance (K), and volume (L). Data were analyzed with Student’s t-test; **P<0.01, 
***P<0.001 vs. untreated control. CA, coronary artery; LCA, left coronary artery; RCA, 
right coronary artery; RV, right ventricle; LV, left ventricle. Scale bar is 200µm. 
 
 
3.3 MNE alters gene expression in the embryonic heart 
To investigate molecular pathways regulating cardiogenesis and vasculogenesis 
during the embryonic stage of development, RT-qPCR was performed on E10.5 ventricles. 
Relative gene levels were quantified to determine if the expression of key transcriptional 
regulators and signaling molecules responsible for EMT, angiogenesis, differentiation and 
growth were affected by MNE. The mRNA levels of, 𝛽-MHC, TGF-𝛽1, Bmp10, eNOS, 
Notch1, Hif-1𝛼, ALDH1a2, CyclinD1, bFGF, Snail1 and Slug were significantly lower in 
hearts with MNE fetuses compared to the control (P<0.05, Figure 12 and 13). mRNA levels 
of Gata4, Tbx5, Nkx2.5, Tbx18, and PKCi were not significantly altered by MNE (Figure 




Figure 12. Gene expression of transcription and growth factors critical to myocardial 
development in E10.5 ventricles of fetuses from MNE and control groups. 
Relative mRNA levels in E10.5 ventricles analyzed by real-time PCR. Data was analyzed 






Figure 13. Gene expression of transcription and growth factors critical to coronary 
artery development in E10.5 ventricles of fetuses from MNE and control groups. 
Relative mRNA levels in E10.5 ventricles analyzed by real-time PCR. Data was analyzed 





To investigate molecular pathways regulating hypertrophic growth during the later 
stages of heart development, RT-qPCR was performed on E18.5 ventricles. The mRNA 
levels of TGF-𝛽1, 𝛽-MHC, CyclinD1, and BNP were significantly higher in hearts with 
MNE compared to the control (P<0.05, Figure 14A-D). 
 
 
Figure 14. Gene expression of hypertrophic growth factors at E18.5 ventricles of 
MNE and control groups. 
Relative mRNA levels in E18.5 ventricles analyzed by real-time PCR. Data was analyzed 




3.4 MNE on Cell Proliferation and Nicotine Exposure on 
Epicardial EMT in the Fetal Heart 
3.4.1 Effects of MNE on Cell Proliferation 
Cell proliferation is required for septation, myocardialization, and EMT, all of 
which contribute to the proper morphogenesis of the heart and coronary vasculature. As 
such, proliferating cells were marked by staining with anti-phosphorylated histone H3 
(pHH3) antibody (1:500, Abcam) (Figure 15A and B). Cell proliferation was evaluated in 
E10.5 embryonic ventricles. The number of pHH3 positive cells were counted in four to 
five sections. The number of pHH3 positive cells in the ventricular myocardium were 
significantly lower in the MNE group compared to the control group (P<0.01, Figure 15C). 
 
Figure 15. Effects of MNE on cell proliferation. 
Representative images of E10.5 embryonic hearts immunostained with anti-phosphor-
histone H3 antibody to measure proliferation in the ventricular myocardium of fetal hearts 
from control (A) and MNE (B) fetuses. Images were taken at constant exposure. Scale bar 
is 20µm. (C) pHH3 positive cells per mm2. Data was analyzed with Student’s t-test; 
**P<0.01 compared to control. 
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3.4.2 Effects of Nicotine on Epicardial EMT ex vivo 
To investigate whether nicotine affected epicardial EMT, E12.5 hearts were 
cultured on a collagen gel to allow epicardial cell outgrowth, and cell EMT to occur (Figure 
16A-C). The distance of cell outgrowth and area of outgrowth was quantified and 
normalized to heart explant area (Figure 16B and C). Nicotine treated cultures had 
significantly less outgrowth as compared to controls (P<0.05, Figure 16D and E). These 





Figure 16. Nicotine inhibits epicardial EMT ex vivo. 
Epicardial cells migrate from cardiac explant culture to become EPDCs and undergo EMT 
to become mesenchymal like, spindle-shaped cells. E12.5 heart explants were cultured on 
collagen coated dishes with or without nicotine treatment (100ng/ml). Three days post-
treatment the distance and area of cell outgrowth (cells that have undergone EMT) was 
quantified. Scale bar is 20µm. Data are mean ± SEM from 9 independent experiments. Data 




3.5 Effects of Maternal Nicotine Exposure on Oxidative 
Stress 
Evaluation of oxidative stress in E10.5 ventricles was measured as evidence for 
oxidative damage. Dihydroethidine (DHE) probe was used to measure levels of superoxide, 
a marker of ROS. Heart sections were pre-treated with superoxide dismutase (SOD), a 
superoxide scavenger, to confirm the fluorescence signal observed was in fact superoxide. 
Images were taken at a constant exposure in five sections of E10.5 hearts from each group 
(Figure 17A-D). Fluorescence was quantified by densitometry. There were significantly 
higher levels of superoxide in the MNE group compared to the control (P<0.05), which 















Figure 17. Effects of MNE on superoxide levels. 
Representative images of fetal hearts at E10.5 immunostained with dihydroethidium 
(DHE) as a probe to measure ROS in the form of superoxide in the ventricular myocardium 
of fetal hearts from control (A) and MNE (C) fetuses. Tissue was pretreated with 
superoxide dismutase (SOD) to confirm fluorescence in both control (B) and MNE (D) 
groups. Images were taken at a constant exposure. (E) Quantification of DHE fluorescence 
intensity by densitometry; data were analyzed with two-way ANOVA, *P<0.05 vs control, 




4-hydroxynonenal (4-HNE) staining was used to measure levels of lipid 
peroxidation, an indicator of oxidative damage. Images were taken at a constant exposure 
in five sections of E10.5 hearts from each group (Figure 18A and B). There were 
significantly higher levels of lipid peroxidation in the MNE group compared to the control 












Figure 18. Effects of MNE on oxidative stress. 
E10.5 immunostained with anti-4-hydroxynonenal (4-HNE) to measure oxidative damage 
in the form of lipid peroxidation in the ventricular myocardium of fetal hearts from control 
(A) and MNE (B) fetuses. (C) Quantification of 4-HNE fluorescence intensity by 
densitometry; data were analyzed with Student’s t-test, means ± SEM, ***P<0.001 vs 




Chapter 4  
4 Discussion 
4.1 Summary of Findings 
The overall aim of this thesis was to evaluate the impact of MNE on cardiogenesis, 
as well as to determine a potential mechanism how nicotine affects heart development. The 
results of this study demonstrate that MNE induced congenital heart defects and coronary 
artery defects in mice fetuses at an incidence of 43% and 31% respectively. MNE caused 
increased levels of ROS in the developing heart. Increased ROS in the fetal heart has been 
demonstrated to contribute to the development of CHDs and CADs in the offspring of mice 
183. In this thesis, I have demonstrated that MNE impairs heart development and coronary 
artery development and provide evidence that use of nicotine replacement therapies during 
pregnancy may not be a safe alternative to cigarette smoking. 
4.1.1 Impact of MNE on Cardiovascular Morphology 
MNE resulted in a higher incidence of CHDs in mice offspring compared to the 
control group. The mouse model of maternal nicotine treatment in this study produced a 
range of mild to severe defects. CHDs can be categorized on level of severity which is 
associated with the patients’ quality of life and perceived health as well as the need for 
intervention for management 189, 190. ASDs, VSDs, thick pulmonary valve, and thick aortic 
valve generally have more simple treatments, and are categorized as more mild defects, 
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although, there are exceptions, as these defects can be associated with poor cardiovascular 
health long-term, which may categorize them as moderately severe 190.  
AVSDs are classified as moderately severe as many patients do not survive past 
childhood without intervention 190. Post-surgical complications for AVSD treatment may 
occur, such as pulmonary vascular disease, conduction disturbances, arrhythmia and 
congestive heart failure 190. The severity of septal defects generally depends on the size and 
location of the septal opening. This opening will result in mixing of the oxygenated and 
deoxygenated blood. This will result in less than normal oxygenated blood being pumped 
into systemic circulation. Consequently, moderately severe septal defects which have a 
larger opening can result in cyanosis. CHDs that are classified as severe require multiple 
complex surgical corrections and lifelong follow up care 191. Defects that are considered 
severe include, double outlet right ventricle (DORV), isolated hypoplastic left ventricle 
(IHLV), and truncus arteriosus. Many of the observed congenital heart malformations have 
been linked to defects related to cigarette smoking in humans 115, 192. To our knowledge, 
the present study defined for the first time various CHDs that are induced by MNE in a 
mouse model. 
Malformations of the coronary vasculature were also observed with MNE. It is 
crucial to identify anomalies of the coronary arteries as many cases can cause severe 
reduction in blood flow to the myocardium 193. Coronary artery anomalies can be classified 
based on the functional relevance of each defect, which can be evaluated by the level of 
resultant ischemia 193. To our knowledge, the present study demonstrated for the first time 
that MNE impairs coronary artery vasculature in fetal hearts of a mouse model.  
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4.1.2 Impact of MNE on Cell Proliferation 
To be able to understand the pathogenesis of CHDs and CADs, it is important to 
evaluate how MNE affects the fetal heart at crucial stages in its development. E10.5 in the 
mouse is the stage when septation, valve formation, as well as vasculogenesis begins. Our 
data showed that MNE resulted in lower expression levels of pro-proliferative genes, 
including CyclinD1, bFGF, Bmp10 and 𝛽-MHC, compared to the control. Notably, 
histological analysis of embryonic hearts at E10.5 also indicated that the number of 
proliferating cells in the myocardium was lower with MNE. 
Highly controlled cell proliferation of cardiomyocytes is critical for normal heart 
morphogenesis during embryonic, fetal and neonatal stages of development 194. Cell 
proliferation is regulated spatially and temporally during development, and the rate of cell 
proliferation peaks at E9.5 and gradually decreases throughout development 195. Proper 
septal formation is dependent on localized temporal and spatial regulation of 
cardiomyocyte proliferation 196. The molecular mechanisms that are fundamental for 
normal heart development and control of cardiomyocyte proliferation and subsequent 
myocardial growth are not yet fully understood 197. CyclinD1 plays a critical role in 
regulating proliferation of cardiomyocytes during normal fetal heart development 198. 
bFGF and Bmp10 also play an important role in stimulation and regulation of proliferation 
and differentiation in the fetal heart 199, 200. BMPs specifically are essential for cardiac 
septation and valve development 24. Deletion of Bmp10 is embryonic lethal and results in 
a severe reduction in cardiomyocyte proliferation 201. 
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Mesenchyme cells of the AV cushions are derived from the process of EMT. To 
cellularize the cushions, these mesenchymal cells migrate into the cardiac jelly and 
proliferate 24. Rapid proliferation is required for normal embryonic development 194. An 
important mediator of cellular proliferation is ROS 202. Basal levels of ROS are vital for 
regulation of normal gene expression and proliferation during development 170, 203, 204. 
Previous work in our lab has demonstrated that tight regulation of ROS levels is required 
for normal cardiac development. Studies have shown that increased ROS production can 
reduce levels of cell proliferation as well as increase apoptosis in the EC cushion 183. 
We have demonstrated that MNE caused lower cell proliferation in the embryonic 
heart which may contribute to the abnormalities in septation in the MNE offspring 
phenotype. Such defects may include ASD, AVSD, truncus arteriosus, and DORV. These 
malformations are associated with increased ROS levels and lower expression of pro-
proliferative genes, CyclinD1, bFGF, Bmp10 and 𝛽-MHC, at E10.5, a critical time point 
for septation events. Based on our data we suggest that pathological high levels of ROS 
interfere with cell proliferative events during normal embryonic heart development.  
4.1.3 Impact of MNE on Epicardial EMT 
To understand the pathogenesis of CADs, the effects of MNE on coronary artery 
development was evaluated. Gene expression analysis of embryonic ventricles at E10.5 
from offspring of MNE mothers had lower expression of the angiogenic factors Hif-1𝛼, 
Snail1, Slug, bFGF, eNOS, Notch1 and ALDH1a2. Expression of these genes indicate that 
EMT and vasculogenic events may be impaired.  
The transcription factor Hif-1𝛼 is a promotor of vasculogenesis during embryonic 
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development 205. It is a key regulator of epicardial EMT and migration of EPDCs into the 
myocardium 206. ROS has been shown to alter Hif-1𝛼. Low ROS levels increase the 
expression of Hif-1𝛼 and promote cardiovascular differentiation, while high ROS levels 
inhibit the expression of Hif-1𝛼 207, 208. Snail1, Slug and ALDH1a2 are downstream of Hif-
1𝛼 and are known to regulate epicardial EMT 65, 209, 210. Endothelial Notch1 expression is 
also necessary to activate the expression of Snail1 24. TGFβs, downstream of Notch1, also 
play an important role in the initiation of EMT. In line with our observation that nicotine 
treatment resulted in lower epicardial EMT, we further demonstrated that the expression 
of Snail1, Slug and ALDH1a2 were lower in the embryonic hearts of MNE mice. Snail1 is 
also regulated by ALDH1a2. ALDH1a2 converts retinaldehyde to retinoic acid, which is 
required at multiple steps of cardiogenesis. Retinoic acid is necessary in a signaling 
pathway that is critical for epicardial formation, epicardial attachment to the myocardium, 
myocardial growth and proliferation, as well as coronary artery development 61, 62. Retinoic 
acid signaling is mediated by bFGF, which, in the embryonic heart, promotes epicardial 
EMT and vasculogenesis. Our results show that MNE lowered the expression of bFGF, 
which suggests that retinoic acid signaling is impaired in the fetal heart with maternal 
nicotine exposed mothers. Thus, MNE impaired both Snail1/Slug and ALDH1a2/bFGF 
signaling, which may lead to lower epicardial EMT and coronary artery malformation in 
the fetal heart (Figure 19).  
Epicardial EMT is a critical process for embryonic coronary artery development 57. 
As explained above, cells from the epicardium undergo EMT and become EPDCs, which 
differentiate into vascular smooth muscle cells and cardiac fibroblasts, which are necessary 
for formation of the coronary vasculature. This study demonstrated that nicotine treatment 
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decreased epicardial EMT potential of E12.5 hearts ex vivo. To our knowledge, this is the 
first experimental evidence to show that nicotine exposure inhibits epicardial EMT of the 
fetal heart. 
The coronary artery phenotype observed in this study bears similarity to hypoplastic 
coronary artery disease. Hypoplastic coronary artery disease, as discussed above, has a 
very high risk of myocardial infarction and sudden cardiac death 109. Our data supports the 
conclusion that MNE could cause hypoplastic coronary arteries in mice. This study 
demonstrated that MNE increased ROS production, lowered Hif-1𝛼, Snail1, and 
ALDH1a2/bFGF signaling pathways leading to disruption of epicardial EMT and coronary 
artery malformation in the fetal heart.  
4.1.4 Thickening of the Ventricular Myocardium 
To help explain the diversity in CHD phenotype that was observed, different 
mechanisms must be evaluated. As discussed above, we observed lower levels of cell 
proliferation during heart development at E10.5, the stage in development when the cardiac 
valves begin to form and septation events commence. The lower level of proliferation does 
not explain the thickened ventricular myocardium phenotype which we observe in many 
of the offspring affected by MNE. Maturation of the myocardium does not occur until the 
later stages of heart development, and further maturation and growth occurs after the heart 
has fully formed 211, 212. Thickening of the ventricles can result from different factors 
including physiological stress on the heart, or a consequence of genetic changes during 
development. Thus, gene expression analysis of various hypertrophic genes were evaluated 
in the embryonic heart at E18.5. Genes that were evaluated include TGF-𝛽1, 𝛽-MHC, BNP 
74 
 
and CyclinD1, all of which had higher expression with MNE compared to the control. The 
expression of these genes was higher with MNE compared to the control, which provides 
evidence that hypertrophic signaling is higher at E18.5, after morphogenesis of the heart is 
complete. 
Cardiac hypertrophy in utero is a result of both proliferation and hypertrophy of 
cardiomyocytes 213. D-type cyclins, such as, CyclinD1, play an important role as both 
proliferation and hypertrophic signaling regulators of cardiac hypertrophy 214. Inhibition of 
cyclin-D dependent kinases has been shown to impair cardiac hypertrophy 214. Increased 
expression levels of ventricular BNP and TGF-𝛽1 have also been demonstrated to be 
associated with cardiac hypertrophy 215, 216. Upregulation of	𝛽-MHC also serves as a 
marker of cardiac hypertrophy 217. The ventricular thickening observed in this study bears 
similarity to ventricular hypertrophy. This qPCR data gives further confirmation of the 
hypertrophic phenotype which was observed. Hypertrophy increases the risk of heart 
failure, and is associated with a very high prevalence of morbid cardiovascular events, 
although some cases of cardiac hypertrophy in infants spontaneously resolve within the 
first year of life 213, 218. Our data supports the conclusion that MNE could cause ventricular 
hypertrophy in mice.  
4.1.5 Mechanism of Oxidative Stress Induced CHDs and CADs 
Maternal nicotine exposure resulted in higher reactive oxygen species (ROS) 
content and level of lipid peroxidation, an indicator of oxidative damage. Excessive ROS 
production can be detrimental to normal embryonic development 219. It has been 
demonstrated that nicotine binds nAChRs resulting in an increase ion influx which 
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increases [Ca2+]i often disturbing intracellular signaling and organelle function 153. This 
increase in [Ca2+]i induces mitochondrial ROS production in the fetus 159. Increased ROS 
production in the mitochondria disturbs endogenous antioxidant roles and is capable of 
lowering cell proliferation 213. A consequence of this ROS overproduction is nicotine-
induced oxidative stress in the cell 153. The mechanism of oxidative stress induced CHDs 
is complex and multifactorial, and has not yet been fully elucidated. Increased ROS during 
embryonic development induces DNA damage, protein and lipid oxidation, and can affect 
cell apoptosis, proliferation, differentiation and inflammation, for which NF-𝜅B, eNOS, 
and TGFβ play a role 213. Increased ROS has also been shown to lead to lower levels of 
nitric oxide bioavailability, usually a consequence of lower eNOS expression. We 
demonstrated that MNE had lower eNOS mRNA expression in the embryonic heart; lower 
eNOS expression can lead to endothelial dysfunction 213. Physiological basal levels of ROS 
also regulate vasculogenesis 220. While normal levels of ROS are critical for normal 
vascular development, excessive ROS production during cardiogenesis inhibits 
vasculogenesis. The present study showed that ROS production was higher in the E10.5 
offspring heart of MNE mice compared to the control. Our study suggests an important 
role of elevated levels of ROS and its signaling in mediating coronary artery abnormalities 
in the offspring of MNE mice (Figure 19). These results are consistent with that elevated 
ROS levels contribute to the development of CHDs and CADs in the offspring of mice 180. 
4.2 Conclusions 
The results of this thesis support our hypothesis and provides evidence of an 
important role of ROS signaling in the pathogenesis of CHDs and CADs. Excess ROS 
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levels induced by MNE alter gene expression profiles that are required for cardiovascular 
development, including myocardial and coronary artery molecular regulators, and this 
leads to the development of CHDs and CADs in the offspring (Figure 19). Furthermore, 
this thesis has provided valuable insight into the role of ROS levels in impairing epicardial 
EMT and heart development. Overall, my Master’s research thesis has broadened the 
understanding of the effects of MNE on heart morphogenesis. Understanding the molecular 
mechanisms by which nicotine affects embryonic heart development can help facilitate the 
improvement of effective interventions and clinical recommendations. To our knowledge, 
this study defined for the first time that MNE in a mouse model induces a spectrum of 
CHDs, and impairs coronary artery vasculature in the fetal heart. These findings have 
important implications for clinical recommendations of nicotine replacement therapies 





Figure 19. Mechanisms of maternal nicotine exposure induced congenital heart 
defects and coronary artery defects. 
Maternal nicotine exposure (MNE) induced oxidative stress via elevated levels of ROS, 
both of which contributed to altered gene expression. This resulted in an inhibition of both 




4.3 Limitations and Future Studies 
4.3.1 Justification of Study Design  
Many studies have demonstrated the detrimental effects of prenatal tobacco smoke 
or nicotine exposure, although determining the underlying mechanisms for these effects 
has proven difficult. This is partly because of the lack of relevant physiological and 
pharmacological models in which tobacco smoke or nicotine can be studied, as human 
subjects have numerous confounding factors that may be hard to control. To be able to 
characterize various birth defects and investigate their molecular mechanisms, animal 
models have been developed to study tobacco smoke or nicotine 221. It is known that 
excessive stress on the mother during pregnancy increases the risk of various birth defects 
including CHDs 222, 223. Many models use continuous infusion from a subcutaneous 
osmotic pump for nicotine delivery as this eliminates the hemodynamic stress on the 
developing fetus that daily handling and injections would normally cause. However, this 
mode of administration does not truly resemble the normal peaks of nicotine levels seen in 
smokers 163. These pumps release a continuous dose of nicotine more resembling the 
delivery of a nicotine patch. Comparison between models also requires many factors to be 
taken into account. For example, increased nicotine metabolism with pregnancy, 
differences in receptor levels, or the different half-lives of nicotine across species, possibly 
requiring a higher dose to elicit the same effects. The half-life of nicotine in humans, as 
mentioned above, is 2 hours; while in rats it is about 54 minutes and mice only 5-7 minutes 
163, 224. As the half-life of nicotine in mice is so short, the plasma levels of nicotine from 
daily injections would likely be negligible. Similar concerns arise with maternal nicotine 
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treatment via drinking water, as the dose with this mode of administration is not constant 
or as accurate. 
Implanted vehicle controls were not used in this study. Due to the price of each 
pump, saline filled osmotic pumps were not implanted into the control mice. To adjust for 
this limitation, mice in the maternal nicotine exposed group in which pumps were 
implanted, were given substantial time for recovery from the surgical implantation of the 
pump, to ensure that the body was not under any physiological stress from surgery when 
breeding was initiated. Surgical implantation of the osmotic pump was done 14 days prior 
to mating to avoid unintended teratogenic effects of ketamine injection or surgery. Mice 
recover quite rapidly from surgical procedures compared to other larger species partly due 
to their high metabolic rate 225. It has been documented that mice can take up to 10 to 14 
days to recover from a midline intraperitoneal incision and implantation 225. Whereas, the 
surgery performed in this study to subcutaneously implant the Alzet pump is considered a 
relatively minor procedure, thus a shorter recovery time is expected. The 14 days given for 
recovery is more than sufficient time to mitigate any unfavourable teratogenic effects from 
surgery. Though this is a limitation of this study, we believe sufficient time was provided 
for full recovery from any adverse effects from the surgical procedure that would have any 
implications to the pregnancy. Thus, the primary teratogenic factor in our model is likely 
to be nicotine-induced oxidative stress.  
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4.3.2 Isolating a Casual Mechanism of CHDs Induced by MNE 
and Its Challenges 
A major challenge in our understanding of maternal nicotine exposure induced 
congenital heart defects is the variable abnormalities among individuals affected by the 
same maternal nicotine dose. This phenomenon could arise from the genetic variability 
between different mothers, as well as genetic variability between littermates. Genetic 
abnormalities or mutations can contribute to the pathogenesis of CHDs 226. Of course, 
embryonic genes that act directly in cardiogenic pathways receive the most attention in 
research. Though, genes that create the gestational environment in the mother also have an 
effect 226. It is just beginning to be understood how genes impact the susceptibility of the 
embryo to CHDs, though currently there is little research in this area. It has been 
demonstrated that polymorphisms within excision repair cross-complementation group 1 
(ERCC1), poly (ADP-ribose) polymerase 2 (PARP2), and ERCC5 genes in the mother, and 
O-sialoglycoprotein endopeptidase (OSGEP) gene in the fetus are associated with 
increased risk of CHDs in the presence of tobacco smoke 227. Though this is tobacco smoke 
and not nicotine alone, this may still provide insight into pregnancies that are more 
susceptible to CHDs compared to others. Due to the limitations surrounding in vivo animal 
models, the specific role of nicotine in embryonic malformations and the mechanisms 
underlying specific CHDs have not definitively been addressed 153. We have demonstrated 
that oxidative stress plays a role in the induction of CHDs, although the exact mechanism 
is likely multifactorial, with genetics playing a primary role.  
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4.3.3 Future Studies  
To further support the results of this thesis, future studies should work towards 
determining if oxidative stress is the main cause of CHDs and CADs induced by MNE. 
Antioxidant treatments could be used to evaluate if normalizing ROS levels would 
normalize gene expression and reduce the incidence of CHDs and CADs in the offspring. 
A major limitation of this study is that it provides no conclusive evidence regarding 
the exact casual mechanism of the specific pathways of the development of different CHD 
phenotypes. Future studies should focus on further investigating a mechanism of the 
hypertrophic phenotype which was observed with maternal nicotine exposure, as this was 
the defect observed with the highest incidence.  
Studies can be taken further to investigate if DNA methylation plays a role in MNE-
induced CHDs and CADs. DNA methylation can inhibit DNA transcription either directly, 
by altering DNA binding proteins which play a role in the initiation of DNA transcription, 
or indirectly, through chromatin remodeling affecting DNA accessibility to proteins 
importation in regulating DNA transcription 228, 229. The rate of DNA methylation is 
regulated by an intricate and complex interplay of genetic and environmental factors. 
Environmental factors such as prenatal exposure to cigarette smoke can be a strong 
modifier of DNA methylation 230, 231. Cigarette smoke could alter methylation through 
DNA damage resulting in a recruitment of DNMTs. Specifically, nicotine, may modulate 
DNA methylation through its effects on gene expression. As nicotine binds to its receptor, 
it causes an increase in intracellular calcium and will lead to the downstream activation of 
cAMP response element binding protein, an important transcription factor for many genes 
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232. Nicotine has been shown to downregulate DNMT1 mRNA levels and protein 
expression, possibly acting through this pathway 233. Previous studies have shown that 
nicotine contributes to the etiology of smoking associated heart defects by its repressive 
effect on myocardial differentiation, suppressing cardiac genes via promotor DNA 
hypermethylation 234, suggesting that DNA methylation may play a role in the development 
of CHDs.  
4.3.4 Clinical Recommendations 
This thesis has provided evidence that MNE during pregnancy increases the risk of 
CHDs and CADs in mice. In addition to cardiac defects, many adverse effects of MNE on 
the fetus have been documented in other studies 156, 235. Thus, nicotine therapies should not 
be recommended during pregnancy due to safety concerns for the developing fetus. The 
highest recommendation for smokers who become pregnant is to quit smoking. Other 
recommendations include behavioural therapy, patient education and acetylcholinesterase 
inhibitors. Acetylcholinesterase inhibitor administration has been demonstrated as a 
pharmacotherapy for smoking cessation to lower nicotine reinforcement in rats and 
smoking behavior in humans. Previous studies have shown that this treatment is at doses 
that are not associated with tolerance or adverse effects 236. Other therapies that have been 
shown effective for smoking cessation in the general public include: bupropion, which was 
originally marketed as an antidepressant medication, but is now marketed for smoking 
cessation 145, or varenicline, a synthetic drug, which was developed as a specific antagonist 
for the α4 β2 nAChR 145. Though the effectiveness of bupropion and varenicline have been 
proven, and they do not contain nicotine, these alternatives should not be recommended 
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during pregnancy, for there are also safety concerns surrounding pregnancy. To use these 
products or NRTs as an aid for smoking cessation during pregnancy, it is only advisable 
when the benefits significantly outweigh the risks. For example, heavy smokers whom 
have failed to quit smoking on numerous accounts and have failed to respond to any 
behavioral therapies, NRTs can be recommended at the lowest effective dose, as the 
detrimental effects that are observed with MNE have been demonstrated to be dose 
dependent 123. Based on the evidence of this study, that maternal nicotine exposure induces 
congenital heart defects and hypoplastic coronary arteries, it is my recommendation that 
NRTs should not be used or recommended during pregnancy. Fetal development is 
extremely delicate and the risk that is associated with nicotine exposure is too significant 
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